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Preface
The central theme of my thesis is the development of new technologies for genetics, genomics,
and biological research. Technological innovation drives scientific discovery, unlocks new
avenues of research, and allows us to ask questions in ways that were previously unavailable.
Throughout biology we’ve seen many examples of this. The development of next generation
sequencing led to the human genome project and an explosion in our understanding of genetics,
CRISPR has given us the ability to perturb biological systems in unprecedented ways, and, more
recently, single cell RNA sequencing has allowed us to gain a better insight into the mechanisms
of differentiation, cell fate decisions and the numerous cell types that make up multi-cellular
organisms. With each major technological advance our understanding of biology has grown in
ways that were previously unimagined.

Throughout my PhD, I worked on three distinct technology development projects, and each is
organized into its own chapter. Chapter one covers DAPES, a method for single cell protein
sequencing. Next, chapter two describes IRIS, a synthetic construct and computational pipeline
that uses trans-splicing to barcode endogenous RNAs and map them back to individual cells.
Finally, chapter three details AROs, short RNA oligonucleotides that recruit RNA binding proteins
to manipulate target transcripts. While there are several re-occurring themes across the
projects, such as sequencing, splicing and splice-site regulation, the projects themselves are
largely independent. Thus, background information and future directions for each project have
been included independently for greater clarity and the ease of the reader. I hope you enjoy
reading this thesis, and that the projects herein inspire new ways to explore and ask questions
about the world around us.
x

Chapter 1:
Using single molecule imaging techniques to develop the next
generation of proteomics
1.1 Introduction
The ultimate goal of proteomics is to be able to identify and characterize all proteins present in a
cell or tissue under a given set of conditions (Wilkins et al. 1996). Proteins execute the majority
of biological processes within living organisms; however, no technology currently exists to obtain
an accurate snapshot of protein abundance and modifications proteome-wide. The
development of such a tool would not only lead to an increased understanding of fundamental
biology but also provide a platform for biomarker discovery for diseases such as cancers, where
early intervention can significantly improve a patient’s chances of survival (K. S. Anderson et al.
2011). Mass spectrometry and immunoassays represent the state of the art in protein detection
and quantification; however, both of these techniques have significant drawbacks in both the
clinical and research arenas. Mass spectrometry lacks the dynamic range and sensitivity to
detect low abundance, clinically relevant proteins in biological fluids, whereas immunoassays
require well characterized antibodies and lack the multiplexing necessary for use as discovery
tools (Fu et al. 2010).

Here, we propose a new method, Digital Analysis of Proteins by End Sequencing (DAPES), to
quantify protein levels by sequencing the N-termini of millions of peptides in parallel. In the final
version, cells of interest will be lysed to generate a complex mixture of proteins that can be subfractionated if desired. The protein sample will then be cleaved into peptides by enzymatic
1

digestion and immobilized on a low-background nanogel surface in a flow cell via a linker
molecule. The N-terminal amino acid of each peptide will then be determined by performing 420 rounds of successive probing, detection and stripping using aminoacyl tRNA synthetase BirA
fusion probes that leave behind a biotin when they identify their respective amino acids. Finally,
once the identity of the N-terminal amino acid is determined, the residue will be removed by
Edman degradation and the full set of probes will be repeated until the entire peptide is
sequenced and mapped back to the proteome.

1.1.1 The birth of proteomics
The term proteome was first used in 1995 by Marc Wilkins to describe all of the proteins
expressed in a given cell or tissue at a specific time or condition. While the proteome is the
direct product of the genome, the variety of proteins present in a cell can exceed that of the
number of genes, as alternative splicing events and post-translational modifications can create
new species of proteins with different functions. The ultimate goal of proteomics is to be able to
identify and characterize all proteins present in a cell or tissue under a given set of conditions
(Wilkins et al. 1996).

1.1.2 2D-PAGE Gels
Although the term had not yet been coined, some of the earliest work in proteomics was
two-dimensional electrophoresis (Klose 1975). Through this technique, thousands of proteins in
a sample can be separated via distinct physicochemical characteristics. The process works by
running the sample on a polyacrylamide gel in two dimensions using different properties of the
proteins for separation. In the first dimension, a process known as isoelectric focusing is used in
2

which a pH gradient spans the gel and electric current is applied. Proteins migrate along the gel
according to charge until they reach the pH of their isoelectric points, at which point they are no
longer charged and remain stationary. The proteins are then separated by size in the second
dimension as on a typical SDS PAGE gel. As it is unlikely distinct proteins will have both the same
mass and charge characteristics, this allows for reasonable separation of most abundant protein
species (Klose 1975).

1.1.3 The Edman degradation reaction
In the 1980s, work began to extract these protein spots from 2D-PAGE gels and sequence
proteins via Edman degradation (Bauw et al. 1989). Edman degradation works by reacting the
N-terminal amino acid of a peptide with phenylisothiocyanate under alkaline conditions to form
a phenylthiocarbamoyl derivative. From here the N-terminal amino acid is cleaved from the rest
of the peptide as a thiazolinone derivative and identified via HLPC or gel electrophoresis. By
repeating the process, each amino acid of a peptide can be identified and the protein sequenced
(Edman and Begg 1967).

1.1.4 The introduction of mass spectrometry to proteomics
With the advent of matrix-assisted laser desorption ionization (MALDI) (Karas and Hillenkamp
1988) and Electrospray ionization (ESI) mass spectrometry (Fenn et al. 1989), the ability to
measure more fragile polar proteins and those with high molecular masses became feasible. It
soon became clear that mass spectrometry could be combined with the then emerging field of
DNA sequencing to identify extracted proteins. Proteins were digested with bond specific
cleaving enzymes and run through a mass spectrometer. The resulting mass to charge peaks
3

produced a fingerprint that could be compared to databases of known proteins (James et al.
1993) (Mann, Højrup, and Roepstorff 1993). With the ever-growing size of protein sequence
databases, mass alone quickly became insufficient to identify proteins, and the concept of
sequence tags was introduced. Partial sequence information obtained via tandem mass
spectrometry was combined with the mass of the protein to identify proteins with greater
accuracy (Mann and Wilm 1994). Using these techniques, numerous partial 2-D databases were
created, including protein maps of various microorganisms, such as Escherichia coli, H. influenza,
Saccharomyces cerevisiae, Bacillus subtilis, and various human fluids and organs (Langen et al.
2000).

1.1.5 Advances in separation resolution
Despite great advances in mass spectrometry, high-resolution separation of proteins continued
to be a major limiting factor in gaining greater coverage of the proteome, with the largest
proteomes mapped containing only a subset of the known possible gene products (Langen et al.
2000). While 2D-PAGE remained an effective method of protein separation, there were many
drawbacks that made it less than suitable for the systems wide direction that the proteomics
field was headed. In order to use proteins separated by 2D-PAGE, each spot on the gel had to be
individually extracted and digested. This was a very tedious and time-consuming process and
significantly limited the ability of proteomics technology to be high-throughput. New techniques
were needed to increase separation resolution, and high-performance liquid chromatography
was explored as a promising solution. The field was revolutionized by the introduction of
multidimensional protein identification technology or MudPIT (Washburn, Wolters, and Yates
2001). Similar to 2D-PAGE separation, MudPIT uses a two-dimensional scheme based on
4

hydrophobicity and charge to separate proteins. A chromatography column is packed with two
different phase materials, a reverse phase (RP) and a strong cation exchange phase (SCX). In the
reverse phase portion of the chromatography, the stationary phase material is hydrophobic, and
hydrophobic molecules are adsorbed onto the column. As a solution of decreasing polarity (the
mobile phase) is passed over the column, different proteins elute from the stationary phase
material and proteins of different hydrophobicity are resolved. In the SCX portion of the column,
ionic interactions retain negatively charged proteins in the stationary phase and proteins are
eluted off by changing the ionic concentration or pH of the mobile phase. A major advantage of
MudPIT is that the chromatography is done inline with the mass spectrometry, reducing the
manual labor of the process. MudPIT allowed for high-throughput, reproducible
chromatographic fractions, which was important for identification of the same peptide at the
same point in different analyses, such as a comparison of different conditions within the same
cell type.

1.2 Current proteomics technology
1.2.1 A typical MALDI-TOF proteomics experiment workflow
There are several typical workflows for a modern mass spec-based proteomics experiment. Most
proteomics experiments begin by isolation of a protein mixture either from tissue, cell lysate or
subcellular compartments. From here proteins are separated via a number of methods to reduce
the complexity of the sample before being analyzed by mass spectrometry. Gel-based separation
techniques include SDS-PAGE (1 dimensional) or 2D PAGE, whereby proteins are separated
based on size and charge differences (described above). Alternatively, multidimensional HPLC
separation may be used as in MudPIT.
5

Peptides are often pre-separated in such a way that proteins are isolated from subcellular
compartments such as secreted proteins, outer or inner membrane proteins, and periplasmic or
cytoplasmic proteins in order to reduce complexity of the protein mixture prior to separation.
Before the separation process, proteins must be dissociated from complexes, and modifications
must be preserved to reflect the state of the protein at the time of collection. The former can be
achieved via chaotropes (compounds that denature proteins) such as urea and guanidinium
chloride, while the latter can be done through protease and phosphatase inhibitors. Nucleic
acids are also removed via the addition of RNAse and DNAse, as these can interfere with
detection and separation. From here, proteins are resolved via one of the above separation
methods, digested with a bond-specific enzyme such as trypsin, and analyzed via mass
spectrometry. Alternatively, some studies take a shotgun approach, whereby proteins are
digested prior to separation and mass spectrometry.

1.2.2 Antibody-based proteomics technologies
Antibody-based protein arrays have also emerged as an alternative to mass spectrometry
proteomics. Analytical arrays consist of well-characterized antibodies printed on micro-arrays
that capture their conjugate proteins from a solution, such as blood plasma serum. Bound
proteins can then be visualized and fold changes compared to a control sample (K. S. Anderson
et al. 2011; Stoevesandt, Taussig, and He 2009). Another notable technology is reverse phase
protein lysate arrays (RPPA). RPPA is like a western blot for numerous samples. Samples are
micro-printed onto nitrocellulose membranes, followed by sequential exposure to wellcharacterized primary antibodies, secondary antibodies, and imaging. This allows for the analysis
6

of hundreds of tissue samples simultaneously (Gonzalez-Angulo et al. 2011) (O’Mahony et al.
2013).

1.2.3 Nanopore-based technologies
Nanopore technologies have also been explored to sequence proteins; however, this solution
has yet to be proven tractable (Howorka and Siwy 2020). Nanopore sequencing of DNA works by
monitoring changes to an electric current as nucleic acids are passed through a protein
nanopore. While this works well for DNA, using this technology to identify amino acids has hit
several pitfalls. Peptides are more compact and heterogeneously charged than DNA. This makes
them difficult to denature and pass through pores. Additionally, while nano-pore sequencing can
use the negative charge of DNA to pull a peptide through the pore, the variety of charges in
peptides make this more difficult, although solutions have been proposed to use DNA oligos to
pull peptides along. Finally, proteins are more chemically complex than nucleic acids, with 20
possible amino acids as opposed to only four DNA bases. This makes identifying each amino acid
accurately a more difficult problem.

1.3 Applications of proteomics
1.3.1 Proteins as biomarkers for disease diagnosis and intervention
A biomarker is defined as a characteristic that can be objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or response to a therapeutic
intervention (Aronson 2005). A major challenge in the diagnosis of diseases such as lung cancer
is the lack of specific biomarkers for detecting and monitoring the disease. Highly predictive
biomarkers can be invaluable in such diseases where early intervention and detection
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significantly improve a patient’s chances of survival (Tang et al. 2013). If such cancers could be
diagnosed in their earliest stages, it could have a huge impact on patient care. This is best
exemplified by the introduction of the pap smear, a cell-based assay to detect cervical cancer,
the introduction of which has reduced mortality rates in women by 74% (Zastrow 1997).

The past decade has shown much promise for the early detection of cancer by monitoring levels
of protein biomarkers in the serum. Epithelial ovarian cancer is usually diagnosed in the
advanced stage and has a poor prognosis. However, when detected early, the five-year survival
rate is 90% (Munkarah, Chatterjee, and Tainsky 2007). CA-125 has emerged as a robust serumbased biomarker for epithelial ovarian cancer that occurs in approximately 83% of patients with
advanced cancer and in only 1–2% of the normal population (Nolen and Lokshin 2012). Prostate
specific antigen (PSA) is another clinically relevant protein biomarker. PSA is routinely used in
clinical practice to monitor the occurrence of prostate cancer, a slow growing but lethal tumor
that is currently the second most common cause of cancer death among men.

1.3.2 Panel-based biomarker screening and computational approaches
Despite the promising results of both PSA and CA-124, neither biomarker is ideal. PSA has a high
false positive rate, which frequently leads to overtreatment of non-life threatening tumors
(Rigau et al. 2013). CA-125 has been shown to be an accurate indicator in only 50% of early stage
cancers, making detection through this method difficult in many cases (Nolen and Lokshin 2012).
While many valuable single-molecule biomarkers may yet be discovered, there has been a
decline in recent years in discovery of such single-protein markers for approved clinical use. One
hypothesis is that single-protein markers are prone to high levels of genetic and environmental
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noise, the idea being that genetic differences between individuals and the heterogeneity of the
disease process might obscure what would otherwise be obvious associations (L. Anderson
2005).

One approach to overcome this barrier has been to look at fluctuations in the abundance levels
and post-translational modification states of multiple proteins simultaneously. Both candidatedriven immunoassay approaches and mass spec-based proteomics, combined with
computational algorithms, have seen success in this area. In one example, candidate-driven
functional proteomics was used to improve breast cancer classification and was able predict
pathological complete response (pCR) in patients receiving anthracycline-taxane-based NST.
Starting with a reverse phase protein lysate array (RPPA) of 146 antibodies to proteins relevant
to breast cancer and 712 tumor samples, a 10-protein signature was developed with higher
predictive value for recurrence-free survival (RFS) and pathologic complete response (pCR) than
typical clinical variables, such as tumor size and nodal status (Gonzalez-Angulo et al. 2011).

Multiple protein-based serum biomarkers have also been used to monitor organ transplant
rejection and complications. Cardiac allograft vasculopathy (CAV), an accelerated form of
coronary artery disease (Ramzy et al. 2005), is a major issue in the long-term survival of cardiac
transplant patients. 50% of cardiac transplant patients will develop CAV in the first several years
post-transplant, and it has been estimated that 15% of deaths in cardiac allograft recipients are
due to CAV (Lin et al. 2013). The most widely used procedure for the diagnosis of CAV is
coronary angiography, an invasive technique that is costly, uncomfortable and risks
complications for patients. Using MALDI-TOF mass-spectrometry and principal component
9

analysis, an 18-protein serum-based biomarker panel was found that could discriminate between
patients with and without significant development of CAV with about 80% accuracy (Lin et al.
2013). In another study, plasma biomarkers identified through similar proteomics methods as
above were used to monitor renal allograft rejection and inform early therapeutic intervention
to minimize graft damage (Freue et al. 2010). Given the above results, it is likely that our ability
to monitor the entire proteome will be key in discovering protein-based signatures of diseases in
the future.

1.4 Limitations of current proteomics technology
1.4.1 Large diversity and dynamic range of biological samples
Although there have been great advances in proteomics technology, the ultimate goal of gaining
a complete snapshot of all of the proteins in a biological sample remains elusive. This is due to
several factors that complicate modern day proteomics. One major issue is the number and
diversity of genes in the genomes of most organisms. It is estimated that there are somewhere
between 20,000 and 25,000 protein coding genes in the human genome (Consortium 2004). In
addition to this diversity, there is a huge amount of variability in the abundance of proteins
within biological fluids. Blood plasma, one of the primary fluids used in clinical diagnostics, has
an extraordinary dynamic range. It is believed that there are over 10 orders of magnitude
between albumin, which makes up over 55% of plasma protein, and the rarest clinically relevant
proteins (N. L. Anderson and Anderson 2002). Meanwhile, the dynamic range of current mass
spectrometry-based techniques is only four orders of magnitude (Arnaud 2006). This is a
significant limitation as many proteins that may serve as key biomarkers in serum are likely
below the dynamic range and sensitivity limitations of mass spectrometry-based proteomics
10

(Krueger 2006). While attempts have been made to deplete these abundant proteins via affinity
chromatography, this introduces variability and co-depletes untargeted proteins that may have
critical biological significance. For example when human serum albumin was depleted, 814
untargeted proteins were removed from the sample as well (Shen et al. 2005). In combination
these issues lead to under-sampling of proteins in samples and a lack of ability to resolve
important low-abundance proteins.

1.4.2 Protein antibody arrays require well-characterized antibodies
Candidate-driven immunoassays have arisen as a potential alternative to mass spectrometrybased proteomics in some areas. These assays work by printing large numbers of antibodies onto
micro-arrays and assaying for protein abundance. However, a major drawback is that these
assays require well-characterized antibodies to be available for all of the protein species in the
assay. This means such assays are limited to only a small subset of proteins in a sample based on
educated guesses made during the design of the experiment. Furthermore, since different
antibodies have different affinities across proteins, these assays are by no means quantitative in
an absolute sense. While antibody techniques have proven to be powerful, they lack the
potential to gain a complete snapshot of a proteome without well-vetted prior knowledge.

1.5 Digital analysis of proteins by end sequencing (DAPES)
1.5.1 Rationale behind DAPES
Proteins are the machinery that drive most biological processes within living organisms, yet to
date no proteomic technology is available to gain a complete quantitative snapshot of protein
abundance and diversity. The past decade has seen large advances in genomics technology
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leading to a deeper understanding of genetics and cell biology. This biological renaissance has
largely been due to better and cheaper DNA sequencing technology and the advances in
bioinformatics that have accompanied it. However, the technology to sequence and quantify
proteins on a comparable scale has lagged far behind our ability to interpret and use such
bioinformatics data. Many parallels can be drawn between the progression of DNA sequencing
technology and the current state of proteomics. Early DNA sequencing technology began with
the ability to sequence short molecules in bulk via Sanger sequencing and eventually matured
into the powerful modern sequencing technologies, such as Illumina sequencing, that exist today
(Braslavsky et al. 2003). The key to this transformation was miniaturization and parallelization of
the sequencing process and our ability to separate and sequence many individual molecules of
DNA simultaneously.

Similar to the way Sanger sequencing allows us to read the base pair sequence of DNA
molecules, the Edman degradation reaction allows us to read the amino acid sequence of a pure
population of bulk peptide. However, no technologies exist today that allow us to read the
sequences of a mixed population of peptides as is present in biological samples. Digital analysis
of proteins by end sequencing, or DAPES, is a proposed method to quantify protein levels by
sequencing the N-termini of millions of immobilized peptide molecules in parallel (Figure 1.1). In
the final version of DAPES, the following sequence of steps will be followed: 1) Cells of interest
will be lysed to generate a complex mixture of proteins that can be sub-fractionated by
chromatographic or electrophoretic techniques if desired. 2) The protein sample will then be
cleaved into peptides by enzymatic digestion and 3) immobilized on a low-background nanogel
surface in a flow cell via a linker molecule. 4) The N-terminal amino acid of each peptide will then
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be determined by probing using aminoacyl tRNA synthetase BirA fusion probes that leave behind
a biotin when they identify their respective amino acids. 5) Florescent streptavidin will be used
to image biotinylated peptides. 6) Biotin and florescent reporters will be stripped away allowing
for a fresh round of probing. 7) Steps 4-6 are repeated for 4-20 rounds of successive probing,
detection and stripping using different AA probes until the N-terminal amino acids of all peptides
are identified. 8) once the identity of the N-terminal amino acids are determined, the terminal
residues will be removed by Edman degradation and steps 4-7 are repeated until the entire
peptide is sequenced. 9) Finally, the peptides will be mapped back to the proteome, and relative
abundance can be calculated.

To accomplish this feat, several significant barriers must be overcome. First, like modern highthroughput sequencing, individual peptides must be able to be separated from one another on a
surface suitable for the sequencing chemistry. Next, peptides must be able to be visualized with
high enough resolution that single molecules can be distinguished from one another. Finally, as
current Edman degradation relies on HLPC to determine the N-terminal amino acid, and it is not
possible to perform such an operation on single molecules, new sequencing technology must be
developed. This will require a way to attach molecules such as biotin acceptor peptides to the
peptides we wish to sequence so that the results of our probes can be visualized.

1.5.2 Ultra-low background nanogel surfaces and single molecule imaging
Recently, it has been demonstrated that single-molecule detection can enable the quantification
of low abundance proteins in complex mixtures such as human serum, a crucial step for
biomarker discovery and a limiting factor in current proteomics technology (Tessler,
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Reifenberger, and Mitra 2009). Such quantification requires the use of surfaces with extremely
low non-specific background adsorption such that probes used to detect individual peptides do
not themselves stick to the surface and cause noise. To this end, much work has been done to
find suitable single-molecule imaging surfaces. Recently, ultra-low background nanogel surfaces
based on multi-armed PEG conjugates have emerged as excellent candidates for this
application (Tessler et al. 2011).

DAPES makes use of a variant of this nanogel using a four-arm PEG-maleimide. Maleimides react
with free sulfhydryl groups, such as those found on the amino acid cysteine, and form stable
thioether linkages. In the final form of DAPES, proteins will first be denatured and digested with
trypsin into short peptides whose cysteines will be blocked by a protecting group. Linker
peptides containing two free cysteines will be attached to the nanogel surface via a reaction with
maleimide through one of their sulfhydryl groups, leaving the other free. Peptides to be
sequenced will then be attached via their C-terminal residues (through an NHS ester) to the
linker peptides on the surface containing free cysteines. This will create a lawn of peptides to be
sequenced, with exposed N-termini in solution and a free cysteine at the base.

1.5.3 TIRF imaging
As the power of DAPES relies on parallelization of the sequencing process, we need the ability to
visualize individual peptides on our nanogel surface. As such, an imaging technique with
extremely high resolving power must be used. Total internal reflection fluorescence microscopy
(TIRF) allows for single molecule imaging with exceptional signal to noise ratios. TIRF works by
illuminating only molecules within a small volume of fluid near the coverslip while not
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illuminating those molecules deeper in the solution. When a beam of light passes from a
medium with a higher refractive index to one of a lower refractive index, some of the light is
reflected while a portion of the light is refracted and passes through at a different angle. TIRF is
achieved by adjusting the angle of the light source such that the refracted beam approaches
parallel to the interface between the two media, i.e., the incident beam is at an angle greater
than or equal to the critical angle for the interface. This creates an evanescent wave that extends
into the medium but decays exponentially with distance from the surface. As the evanescent
wave lacks the intensity to illuminate fluorophores beyond ~100 nm, this allows selective
illumination of fluorophores close to the coverslip, largely eliminating background illumination
(Reck-Peterson, Derr, and Stuurman 2010). By leveraging TIRF microscopy, we have the resolving
power to visualize individual peptides on a nanogel surface (Tessler, Reifenberger, and Mitra
2009).

1.5.4 Aminoacyl tRNA synthetases as N-terminal amino acid probes
Currently, no high-throughput way to sequence multiple proteins in parallel exists. While Edman
degradation can remove one amino acid at a time from individual peptides, DAPES will require
some way to elicit the identity of the terminal amino acids removed. Aminoacyl tRNA
synthetases are the enzymes that are responsible for the correct addition of free amino acids to
tRNAs, the molecules that recognize three base codons during translation and ensure the correct
amino acids are added to a growing peptide. As such, tRNA synthetases contain sensitive
recognition domains capable of identifying specific N-terminal-oriented amino acids based on
their side chains (Onesti et al. 2000). DAPES will leverage probes based upon the amino acid
recognition domains of tRNA synthetases being created by our collaborators in the Havernak lab
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at Washington University in St Louis. A major advantage of DAPES over immunoassays and
antibody-based arrays is that amino acids are conserved across species. Thus, once a set of
probes is created, they can be used to sequence proteins from any organism.

While these probes have good specificity for their specific amino acid targets, we have found
that they also bind to off-target amino acids to varying degrees. This is to say that while a probe
may have high affinity for its target amino acid, it may also have some affinity for other amino
acids with similar side chains. While this may seem like a drawback, DAPES will account for this
leaky specificity computationally to minimize the total number of probes necessary for
sequencing. By creating a matrix of the specificities of each probe to each amino acid, we can
assign patterns of binding to different amino acids. For example, we may be able to identify an
amino acid such as lysine using the binding patterns generated by exposing it to non-lysine
specific probes. Using the information content generated by multiple probes to identify a single
amino acid means each amino acid only needs to be exposed to a subset of available probes to
gain a high probability of identification of the current N-terminal amino acid. Preliminary in silico
data suggests mapping to the human proteome can be accomplished for over 90% of possible
peptides with as few as four probes, given a read length of 15 residues. Using this method, it is
likely that far fewer than 20 tRNA synthetases will be needed to confidently sequence a quantity
of amino acids sufficient to identify a given peptide.

1.5.5 Biotinylation as a marker for binding events.
While our tRNA synthetase probes have good specificity for their amino acid targets, their fast
dissociation rates make them problematic for single molecule imaging. Thus, DAPES will leverage
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an approach using biotinylation to mark peptides that have been bound by probes. Biotin is a
naturally occurring co-factor for metabolic enzymes that becomes covalently bound through the
action of specific protein–biotin ligases, such as BirA (Reche 2000). In our scheme, BirA will be
fused to our tRNA synthetase probes, and a 23-amino acid biotin acceptor peptide will be
chemically attached to the free cysteine of our linker (described above). This method will
leverage the high specificity of our probes while overcoming their less desirable high dissociation
constants (Kd) by covalently attaching biotin to the acceptor peptides on the sequencing
peptides they bind to. We will be using a weakened version of the biotin acceptor peptide such
that background biotinylation is low, making use of the binding energy of the tRNA synthetase to
provide specific biotinylation (Fernández-Suárez, Chen, and Ting 2008). In short, any peptides
whose N-terminal amino acids are positively identified by a tRNA synthetase probe will become
covalently marked with biotin. We will then use fluorescent streptavidin to visualize the
biotinylated peptide on our surface. One common issue with fluorescent probes in single
molecule imaging is that fluorescent molecules tend to have a high amount of non-specific
background binding. Biotin streptavidin binding is one of the strongest non-covalent interactions
known in nature (Kd 10-15), several orders of magnitude higher than that of commonly used
antibodies (Boer et al. 2003). By using this strong streptavidin-biotin interaction to label our
binding events, we can minimize the concentration of fluorophore in solution, dramatically
reducing non-specific binding. Once the N-terminal amino acid is identified, and the biotin
acceptor peptide is tagged, we will remove spent (biotinylated) biotin acceptor peptide from the
molecules via a reducing agent such as TCEP and replace them with fresh (non-biotinylated)
acceptor molecules so that the next amino acid can be identified post-Edman degradation.
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1.5.6 Repeatable click chemistry and Edman degradation
During each round of sequencing, the terminal amino acid of the peptide will have to be exposed
to several probes in order to determine its identity. However, as the biotinylation reaction, which
marks whether or not a probe has bound, is not reversible, we need some way to “reset” the
acceptor peptide to allow for a new binding event to be registered. To do this we turn to
reversible thiol click chemistry. This allows us to remove the biotinylated acceptor peptide from
each peptide to be sequenced between probing and replace it with a new acceptor peptide
ready to receive biotin. 2,3-Dibromomaleimide is a small molecule that can quickly, efficiently
and specifically bind to up to two thiol groups per molecule (Tedaldi et al. 2009; Smith et al.
2010). The reaction works via an addition-elimination mechanism whereby a bromine acts as a
leaving group and is replaced by a thiol on the succinimide ring. Recently, it has been shown that
2,3-dibromomaleimide can be used to replace reduced cysteine disulfide bonds in proteins
(Jones et al. 2012). In the final envisioned form of DAPES, we will use 2,3-dibromomaleimide as a
glue to bridge our biotin acceptor peptide to our linker. The biotin acceptor peptide will be
synthesized such that it will contain a reduced cysteine as its C-terminal residue, providing a free
thiol group. 2,3-Dibromomaleimide will be attached to a free cysteine on the linker that anchors
the peptide targeted for sequencing to our surface. From here, the biotin acceptor peptide will
be reacted to the 2,3-dibromomaleimide linker conjugate, eliminating the remaining bromine
and linking the molecules together. Unlike conventional maleimide-thiol bonds, which are
irreversible, thiol bonds formed with 2,3-dibromomaleimide can be broken using a strong
reducing agent such as BME. Thus, we can use BME to remove biotinylated, streptavidin-marked
acceptor peptide after each round of probing and visualization and regenerate fresh nonbiotinylated biotin acceptor peptides on each molecule we want to sequence.
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1.5.7 Edman degradation: removing the identified N-terminal amino acid
The Edman degradation reaction is able to remove a single N-terminal amino acid from a
peptide. After the N-terminal amino acid has been probed and identified, it will need to be
removed so that a new round of probing can begin and the next amino acid in the chain can be
identified. This will be accomplished by exposing the peptides to a single round of Edman
degradation. Previous work has been done to ensure that the nanogel surface can withstand the
harsh reagents used in Edman degradation and maintains its integrity for future reactions. Unlike
traditional Edman based sequencing, DAPES will not suffer from phasing issues as each peptide
on the surface is sequenced and identified individually.

1.6 Results
1.6.1 Ultra-low background nanogel surfaces and single-molecule TIRF imaging
Single-molecule quantification requires the use of surfaces with extremely low non-specific
background adsorption such that probes used to detect individual peptides do not themselves
stick to the surface and cause noise. To this end, much work has been done to find suitable
single-molecule imaging surfaces. Recently, ultra-low background nanogel surfaces based on
multi-armed PEG conjugates have emerged as excellent candidates for this application (Tessler
et al. 2011). DAPES uses a four-armed PEG maleimide as a substrate for peptide attachment.
Glass is exposed to 3-mercaptopropyltrimethoxysilane to create free thiols on the glass surface
to which the nanogel surface can attach through an irreversible maleimide-thiol bond. As many
of the maleimides are still free on the top of this nanogel after attachment, peptides with Cterminal cysteine (containing free thiols) can then attach to the nanogel surface through a
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second thiol maleimide bond. This creates a surface that repels non-specific substrates such as
fluorophores, allowing us to tag and visualize individual peptides (Figure 1.2A). By attaching a
biotinylated peptide to this surface and exposing it to fluorescently labeled streptavidin, we
show that single molecules can be visualized via TIRF microscopy (Figure 1.2B). Few fluorescent
spots are seen in the no-peptide control, indicating that the surface effectively repels
streptavidin in the absence of biotinylated peptides.

1.6.2 Deactivation of maleimides with hydrolysis
Peptides to be sequenced are chemically bonded to linker peptides ending in cysteines, whose
R groups have free thiols that can react with the maleimide surface (Figure 1.3A). After the
peptide is attached to our nanogel surface via a thiol-maleimide interaction, free maleimide on
the nanogel must be inactivated to prevent unwanted interactions with thiols in subsequent
steps (such as the attachment of a biotin acceptor peptide to the cysteine of our sequencing
peptide). We hypothesized this could be done through the hydrolysis of maleimides at high pH
without disturbing the nanogel surface (Figure 1.3B). We prepared glass slide flow cells with a
PEG-maleimide surface and exposed the slides to phosphate-buffered saline (PBS) for 1 hour at a
range of pHs (Figure 1.3C). Surfaces were then washed with neutral PBS and exposed to
biotinylated peptide with free C-terminal cysteines and probed with fluorescent streptavidin to
assay for peptide attachment to the nanogel surface. At pH 7, nearly the entire imaging area is
fluorescent, indicating wide-spread attachment of the peptide and active maleimide. At pH 8 we
see a weakening of this signal, indicating fewer available maleimides reacting to the peptide. At
pH 10 we observe a nearly compete ablation of signal.
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In a second experiment, PEG-maleimide surfaces were exposed to pH 10 solutions of PBS for 30
min, 1 hour and 2 hours as well as a control solution of pH 7 PBS for 2 hours (Figure 1.3D). A time
dependent decrease in peptide attachment to the PEG-maleimide surface can be seen in the
pH 10 samples while peptide readily attaches to the pH 7 exposed surfaces.

1.6.3 Probe specificity and evidence that biotinylation works on our surface
Next, we wanted to show that specific N-terminal amino acids can be recognized by our
biotinylation scheme (Figure 1.4A). To investigate this, we fused the biotin acceptor peptide to a
peptide with a known sequence ending in tryptophan (Wseq-BA) (Figure 1.4B). This peptide
served as a proxy for the final construct where biotin acceptor peptide would be attached to an
internal cysteine on the linker peptide via a reversible chemical reaction. The peptide was
attached to a PEG-maleimide surface as described above and exposed to tryptophan-specific
tRNA synthase probe fused to BirA, an enzyme that adds biotin to the biotin acceptor peptide
sequence. Biotinylation events were enriched in the peptide ending in tryptophan over the
biotin acceptor peptide on its own, and little to no signal was observed in the peptide sequence
lacking any biotin acceptor peptide (Figure 1.4C).

1.6.4 Protecting group on peptide to create a free cysteine
One major issue with our biotinylation scheme that had to be overcome was the double
attachment of cysteine to the PEG-maleimide surface (Figure 1.5A). As attachment of the biotin
acceptor peptide to a free thiol on the sequencing peptide uses the same maleimide chemistry
as attachment of the sequencing peptide to our nanogel surface, a t-butyl protecting group was
added to the internal cysteine of the sequencing peptide to prevent this group from interacting
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with the nanogel (Figure 1.5B). Once peptides are attached to our nanogel surface and excess
maleimides inactivated through hydrolysis, the t-butyl group can be cleaved off using a reducing
agent such as TCEP. Once the protecting group on the sequencing peptide is removed, a free
thiol is created, allowing the attachment of biotin acceptor peptide via a disulfide bond. In the
final version 2,3-dibromomaleimide will be used to attach the biotin acceptor peptide reversibly.
However, to test if our internal cysteine was protected by t-butyl, we exposed various peptides
to TCEP and then tried to attach a pre-biotinylated acceptor peptide via a C-terminal maleimide.
We then probed the surface with fluorescent streptavidin and quantified attachment of
biotinylated peptides via TIRF microscopy (Figure 1.5C). A no-peptide control was used as a
baseline and shows little to no fluorescence when exposed to streptavidin. A peptide lacking an
internal thiol (Wseq1C), and thus unable to bind biotinylated peptide through a maleimide
reaction, shows a similar lack of florescence to the no-peptide control. This served as a control
for a protected peptide. Next, in the absence of TCEP, our t-butyl protected peptide (WseqPro)
shows similar results as the peptide lacking an internal thiol, demonstrating protection of the
cysteine residue. Finally, we show that WseqPro in the presence of TCEP frees the internal thiol,
allowing it to react with our biotinylated maleimide peptide, creating a strong fluorescence
signal.

1.7 Discussion
1.7.1 Analysis and conclusions
In this section we have overcome several key roadblocks to implementing DAPES, Digital Analysis
of Proteins by End Sequencing, a technology to quantify protein levels by sequencing the
N-termini of millions of peptides in parallel. One of the key requirements of DAPES was a low
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background surface that could be used to attach peptides for microfluidics and TIRF microscopy.
We demonstrated that 4-arm PEG maleimide can be attached to a glass coverslip to create a
nanogel that can be used to attach peptides via thiol chemistry while repelling non-specific
proteins and fluorophores. We have also shown that this surface can be used to visualize
peptides with single molecule resolution. To make use of this surface, we needed a way to
inactivate unused maleimides after peptide deposition. To accomplish this, we used high pH to
hydrolyze the maleimide bond and have also shown that unused maleimides on the PEG do not
continue to attach peptides. Next, we showed that a fusion of a short peptide with the biotin
acceptor molecule AP-3 can be used to mark when N-terminal amino acids are identified by
tRNA synthetases fused to BirA and that these probes preferentially biotinylate molecules with
their corresponding N-terminal amino acids over biotin acceptor peptide alone. Finally, we have
shown that the internal thiols of such peptides can be prevented from sticking to the maleimide
surface via protection using a t-butyl protecting group, that this group can be cleaved to create
an active S-S bond post-surface deactivation, and that this bond can be used to attach additional
peptide sequences, such as biotin acceptor peptides. Overall, we have made several leaps
forward in realizing the technologies necessary for DAPES to become a reality.

1.7.2 Future directions
While we have made significant advances towards DAPES, several outstanding issues still need to
be solved before it can be implemented as a peptide sequencing technology. While we have
been able to show that a tryptophan tRNA synthetase fused to BirA can preferentially bind to
N-terminal W residues over biotin acceptor peptide alone, we still do not know the error rate of
other tRNA synthetases fused to BirA or their level of cross reactivity with other peptides. In pilot
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experiments, we have seen that tRNA synthetases do not always have the same specificity
profiles after BirA has been attached. The full set of BirA-fused tRNA synthetases still need to be
tested under DAPES conditions to see if we can overcome this cross-reactivity via computational
means.

Next, we will need to demonstrate that the biotin acceptor peptide can be recycled on the
peptide thiol bond. So far, our experiments have made use of maleimides for one-time covalent
bonds to test specific parameters of the system. While 2,3-dibromomaleimide seems promising
as a repeatable and recyclable attachment schema for removing spent biotinylated acceptor
peptide and replacing it with non-biotinylated acceptor peptide, specific protocols still need to
be developed to implement this in our system.

One potential issue with our amino acid probes is that tRNA synthetases may not recognize
certain posttranslational modifications when used in actual biological samples. This could lead to
gaps in our sequence if the probes do not bind at all or incorrect binding patterns if the probes
do bind but with different affinities than we expect to see. New probes, such as those recently
created for phosphoserine and phosphotyrosine, may need to be developed to account for such
modifications. However, it is possible that this may not pose a major issue when we proceed to
serum-based sequencing. As we will be mapping our sequences back to the human proteome,
gaps and errors in the sequence can be overcome through common alignment algorithms.

Once a reliable protocol is developed, quality control experiments will need to be performed to
understand error rates and the modality of such errors. The number of peptides that are
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identified correctly through their biotinylation patterns will be an important metric of success for
DAPES. To measure this, we will use a population of peptides of known sequence during initial
experiments. This will not only allow us to quantify the frequency that sequencing errors occur,
but also give us an idea of types of sequencing errors. For example, one error that may occur is
that a subset of peptides may retain their N-terminal amino acids after the Edman reaction. This
could result in either a complete lack of binding if the PITC intermediate does not cleave properly
or re-probing of the same amino acid twice. In a real-world application of DAPES, experimentally
determined sequences will be mapped back and aligned to the human proteome such that
potential gaps and repeats will be accounted for. However, during initial experiments it will be
important to gain an empirical measure of the frequency of these events such that the process
can be improved. Preliminary in silico experiments show DAPES to be fairly error tolerant,
requiring only 6-10 amino acids to be sequenced from each peptide fragment (depending on the
number of probes) to uniquely map >90% of the sequences back to the human proteome.

1.7.3 Closing remarks
We believe DAPES has the potential to have a major impact on the world of proteomics. The
current best proteomics technologies have inherent drawbacks that restrict their usefulness as
diagnostic tools in clinical settings and discovery tools in the laboratory. Much like DNA
sequencing technology proceeded from bulk sequencing of a pure population of molecules to
the high-throughput, highly parallel genomic sequencing we see today, DAPES will have a similar
effect on proteomics. As DAPES is, in essence, a counting method and peptides are sequenced
individually, it does not suffer from the dynamic range issues of modern mass spectrometrybased proteomics. Additional DAPES runs can provide more information, allowing us to have
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highly accurate quantitative measurements of biological samples, regardless of dynamic range.
In addition, unlike antibody-based arrays, the number of probes required for DAPES is minimal
and, once developed, can be used across species. A fully realized DAPES protocol could allow for
biological fluids of unprecedented dynamic ranges to be quantified with both high sensitively
and accuracy. If DAPES can be brought to fruition, it will make an invaluable tool for both
biomarker discovery and clinical applications.

1.8 Materials and Methods
1.8.1 Flow cell glass preparation and peptide deposition
A flow cell was assembled using a silicon gasket, microscope slide, and glass coverslip. The
coverslip was treated with (3-mercaptopropyl)trimethoxysilane to create free SH groups on the
glass, forming the base layer of our sequencing surface. Slides were then dipped in acetone to
wash off excessive reagent and heated at 40C to evaporate excessive acetone. From here, 4-arm
PEG-maleimide nanogel was applied, reacting with the free SH groups on the glass and creating
our low background surface. Each PEG molecule has 4 reactive maleimides, and only some are
taken up by the SH bond to the glass. This creates a surface that is repellent to most
fluorophores and peptides but has active maleimides that can react with additional thiols to
form covalent bonds.

1.8.2 Sequencing peptides used
All peptides for experiments were ordered from Biopeptide Co., LLC at 10 mg and suspended in
DMSO. Peptides were aliquoted into PCR tubes to avoid repeated freeze-thaw cycles and kept at
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minus -20 oC. The sequence of the “Wseq” peptide used in the experiments was as follows:
W-M-R-G-E-A-C-E-S-G-C-OH. “Wseq-Pro” consisted of the same sequence but with the internal
cysteine protected by a t-butyl group: W-M-R-G-E-A-C(S-tbu)-E-S-G-C-OH. A biotinylated peptide
used to assay for peptide attachment to the maleimide surface, “KBC24” was as follows:
K[biotin]-G-K-G-G-D-I-F-E-A-Q-K-I-E-W-H-E-G-G-A-P-A-V-C-OH. The biotin acceptor peptide used
to accept biotin from the BirA protein was as follows: G-K-G-G-D-I-F-E-A-Q-K-I-E-W-H-E-G-G-A-PA-V-C-OH. A pre-biotinylated acceptor peptide, “pre-Biotin-AP-mal” used to attach to the
internal thiol of Wseq-pro was as follows: K[biotin]-G-K-G-G-D-I-F-E-A-Q-K-I-E-W-H-E-G-G-A-P-AV-C-(s-s-mal).

1.8.3 Deposition of peptides on PEG-maleimide surface
A 10 ul pipet was used to wash flow cells with pH 7 PBS three times prior to deposition of
peptide on flow cells. Next, sequencing peptides were applied at single molecule level
concentrations. The free thiol groups on the cysteines of the c-terminus of the peptide react
with the maleimide surface to create irreversible covalent bonds, orienting the peptides with
their N-termini facing into solution. Peptides were left in the flow cell for 1 hour to allow
sufficient time for the reaction to take place. Flow cells were then washed again three times with
pH 7 PBS to remove residual peptide from the surface.

1.8.4 Deactivation of unreacted maleimides on nanogel surfaces
After peptides are applied, free maleimides on the nanogel surface needed to be deactivated to
prevent them from forming additional covalent bonds with unprotected cysteines in later steps.
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PBS at pH 9 or greater was applied to flow cells and left to react for 2 hours. This hydrolyzes the
maleimide ring, deactivating the molecule. Following high pH incubation, flow cells were washed
three times with pH 7 PBS.

1.8.5 Activation of t-butyl protected thiols on internal cysteines of peptides
The thiols of internal cysteines were necessary for the addition of biotin acceptor peptide (biotin
AP) to the peptide being sequenced. To prevent this peptide from reacting with free maleimides
during peptide deposition on the maleimide surface, these thiols were protected by a t-butyl
group. Once the peptide was deposited and the excess maleimides deactivated by high pH, this
group was removed by incubation of the flow cell in the reducing agent TCEP for 1 hour at room
temperature. This created a free thiol on the internal cysteine that could be used in future
reactions, such as attachment of biotin acceptor peptide via a di-thiol (reversable) or maleimide
(irreversible) bond.

1.8.6 Probing of peptides BirA-tRNA synthetases
BirA-tRNA synthetase probes were designed and purified by the Havernak lab at Washington
University. BirA-tRNA synthetase probes were applied to the flow cell, allowing the probes to
biotinylate the biotin acceptor peptides of those sequencing peptides with exposed N-terminal
amino acids that the probes recognize. After 1 hour of incubation at room temperature, probes
were removed by three washes of pH 7 PBS, followed by 1 hour of probing with florescent
streptavidin and an additional three washes of pH 7 PBS. Flow-cells were left in a final wash of
pH 7 PBS for imaging.
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1.8.7 Single-molecule imaging of peptides
A custom-built TIRF microscope setup was used to image single molecule peptides on the
nanogel surfaces. The flow cell was not moved from the microscopy stage so that subsequent
probing could identify the same peptide on the slide via position. This is key to our single
molecule peptide sequencing. Custom software and precision motors were used such that three
to five images could be taken on each flow cell, and the same positions could be found later.
Subsequent microfluidics, such as additional washing, probing and Edman degradation was done
on the stage of the microscope so as not to disturb these positions. This enables us to identify
the locations of individual peptides and which probes bound to them, allowing us to sequence
these peptides via slide position.
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Figure 1.1

Figure 1.1 Overview of DAPES. (1) Cells are lysed, and proteins extracted. (2) Proteins are cleaved
into peptides. (3) Peptides are fused to acceptor molecules and attached to nanogel surface. (4)
N-terminal amino acids (AAs) are probed and marked by reporters. (5) Reporters are imaged and
location in the flow cell is recorded. (6) Reporter molecules are stripped. (7) Steps 4-6 are repeated
for different AA probes. (8) Edman degradation removes the terminal AA from each peptide and
the process is repeated until all AAs have been sequenced. (9) Sequenced peptides are mapped
back to the proteome.
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Figure 1.2

Figure 1.2 Ultra-low background nanogel surfaces (A) Schematic of peptide attached to a low
background PEG maleimide nanogel surface. The nanogel repels non-specific fluorescent
molecules. (B) Biotinylated peptide vs no peptide on 4-arm PEG maleimide nanogel surface after
one hour exposure to Streptavidin Alexa Flour 647 (5 ng/ml). Single biotinylated peptides can be
visualized and quantified by TIRF microscopy, while in the no-peptide sample the fluorophore does
not stick to the surface.
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Figure 1.3

Figure 1.3 Maleimide nanogel surfaces can be deactivated using high pH. (A) Schematic of a
single-molecule peptide attached via a thiol bond to a nanogel surface coated with maleimides.
(B) Maleimides undergo hydrolysis in high pH and no longer interact with thiols.
(C) PEG-maleimide surfaces exposed to varying levels of pH, probed with biotinylated peptides,
and visualized via streptavidin. (D) Time course of high pH exposure of PEG -maleimide surface.
Longer incubation times at pH > 10 inactivate more maleimide, leading to fewer peptides
binding.
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Figure 1.4

Figure 1.4 tRNA synthetase probe fused with BirA biotinylates peptides based on N-terminal
amino acids. (A) Proposed form of peptide probing. Biotin acceptor peptide (Biotin AP) is
attached to the linker peptide by a reversible dithiol bond. (B) W-seq peptide (peptide ending in
tryptophan) is fused directly to a biotin acceptor peptide as a proxy for the final construct. (C) No
peptide surface, biotin acceptor peptide only and W-seq fused with biotin acceptor peptide were
exposed to a tryptophan-specific probe fused with BirA, then exposed to florescent streptavidin
to assay for biotinylation.
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Figure 1.5

Figure 1.5 T-butyl protecting groups prevent internal thiols on linker peptides from binding to
maleimide surface. (A) Without a protecting group, the internal thiol, reserved for reversible
addition of a biotin acceptor peptide, binds to the nanogel surface. (B) A t- butyl group protects
the internal thiol and can be cleaved by reduction with TCEP. This leaves a free thiol that can be
used to reversibly attach a biotin acceptor peptide. (C) Peptides attached to a PEG maleimide
surface, deactivated via pH hydrolysis. TCEP was added to remove the t-butyl group, and the
surface was probed with biotin acceptor peptide and fluorescent streptavidin.
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Chapter 2:
Internal RNA Identifier Sequencing. A technology for scRNA-seq
barcoding and RNA trans-splicing screening and analysis
2.1 Introduction
2.1.1 Single cell RNA sequencing
Understanding what factors drive cellular identity has been a long-standing goal in biology. While
all cells in an organism share identical genomes, they perform a diverse array of specialized
functions depending on the subset of transcripts they express. Transcriptomic technologies, such
as RNA-seq, aim to tackle this problem by analyzing which genes and splice variants are
expressed in different tissues. However, even at the tissue level, bulk RNA-seq does not provide
the resolution necessary to observe the wide variety of differentiation and specialization that
takes place on the cellular level (Hwang et al., 2018). The major drawback to bulk RNA-seq is that
it provides an average expression of transcript levels for each gene across all cells in a sample.
This proves to be especially problematic with complex tissues such as the brain, where numerous
cell types are interwoven, making transcriptomic data from whole brain extract, and even
substructures within the brain, a poor representation of the cells they contain (Swartzlander et
al., n.d.). Furthermore, there is a growing body of evidence that even stochastic transcript
variation within cells of the same type is important for cell fate determination. For example,
transcriptional cell to cell variability in stem cells has been shown to impact differentiation
decisions in response to stimuli (Eldar & Elowitz, 2010). Heterogeneity in cancer is also a concern
as some subpopulations of tumorigenic cells may be more likely to metastasize or resist
treatment than others (Meacham & Morrison, 2013). Thus, while bulk RNA-seq has proven to be
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an impactful tool in biology, data from bulk experiments is likely to miss critical observations that
are obscured due to limitations of the technology.

Single cell RNA sequencing (scRNA-seq) is the name of a set of technologies that aims to solve
this problem by analyzing transcriptomes at the cellular level. These technologies aim to
separate the transcriptomes of cells so that they can be sequenced and analyzed individually.
Early work in the field that began with single cell amplification of cDNAs (Brady et al., n.d.;
Eberwine et al., 1992), was subsequently applied to microarrays (Klein et al., 2002), and
ultimately next-generation sequencing (Tang et al., 2009). While the development of several
low-throughput single cell cDNA and RNA sequencing techniques provided early steppingstones
for the field it wasn’t until the development of high-throughput microfluidic separation
techniques such as Drop-seq (Macosko et al., 2015), that large scale scRNA-seq experiments
became practical.

2.1.2 Basic workflow of a scRNA-seq experiment
Typical scRNA-seq experiments involve several common steps: single cell isolation, cell lysis,
cDNA generation and amplification of cDNA into a sequenceable library. First cells and tissues
are separated into single cell suspension in some manner. Early methods relied on limiting
dilution to achieve this by lowering the concentration of cell suspension and plating aliquots of
the suspension into wells. Each aliquot of the suspension would have on average 0.5 cells such
that, on average, one third of the prepared wells would contain a single cell with the rest of the
plate being empty (except for a small number of doublets). While this method was effective, it
was highly inefficient and low-throughput. Flow cytometry can also be used to plate single cells,
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with the added advantage of being able to sort for cells using fluorescent markers, however this
method is also considered to be low-throughput by modern standards. Today, most scRNA-seq
experiments rely on several variations of microfluidics to rapidly separate thousands to millions
of cells. These microfluidic methods are both more cost effective and less labor intensive than
previous techniques and are used in most scRNA-seq experiments today.

After separation, cells are lysed, exposing their contents and cDNA is generated for sequencing.
RNAs are barcoded during this step so that transcripts can later be mapped back to individual
cells. Cells are typically lysed using a hypotonic buffer, after which several methods of barcoding
are used depending on the technology. Most methods consist of hybridizing the poly-A tails of
the RNA with a barcoded poly-T sequence and preforming first strand DNA synthesis using a
reverse transcriptase capable of template switching, such as murine leukemia virus reverse
transcriptase. Second strand synthesis is then preformed starting from the template switched
primer and this round of synthesis captures the cell barcode, unique molecular identifiers (if
applicable) and priming site for future amplification rounds. This double stranded DNA is then
amplified and tagmented to create a library suitable for next generation sequencing.

2.1.3 Applications of scRNA-seq technologies
The landscape of cellular diversity is extremely complex and not all cell types can be identified
using a single molecular marker. To further complicate the problem, expression differences and
subtypes exist even in cells within the same canonical classification. As we delve deeper into the
question of what makes one cell type different from another, we find that this question often
cannot be answered by a single outstanding factor. Rather expression differences across
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numerous interacting genes combine to define cellular identity. One major application of scRNAseq data is to explore this question though clustering of single-cell transcriptomes. This allows us
to identify new subtypes of cells, which may perform specialized functions, that are unable to be
resolved using bulk RNA seq data. Due to the large complexity of single-cell data, principal
component analysis is widely used to reduce dimensionality by projecting the data into twodimensional space so that humans can more easily interpret it. Other methods to reduce data
dimensionality such as t-distributed stochastic neighbor embedding (tSNE) are also frequently
employed to help visualize how similar cells cluster in a data set. Once dimensionality is reduced,
resulting clusters can be identified as being representative of different cell types. The biological
functions of these cells can then be investigated, and unique cell markers can be identified from
the transcriptomic data to help separate and study these cells in future experiments.

In addition to identifying new cell types, scRNA-seq data can also be used to understand
differentiation, track cellular lineages, and understand responses to stimuli. When undergoing
differentiation, or in response to a stimulus, individual cells respond at highly variable rates. In a
single snapshot in time, several cells in various states of progression are present in the same
sample. This lets us employ a method known as pseudotime to single cell data sets, which allows
us to reconstruct the path of these cellular dynamics using the presence of these intermediate
states. The concept of pseudotime was first introduced in the program Monocle and
demonstrated on differentiating skeletal myoblasts (Trapnell et al., 2014). In pseudotime, each
cell in the experiment represents a distinct time point in a continuum of states. For example, in a
differentiation experiment, a stimulus is introduced, and several time points are taken for scRNAseq. The algorithm then organizes the data by differentiation progress, rather than time,
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maximizing the transcriptional similarity between each cell and the next on the timeline. This
data is then represented in a dimensionally reduced, human readable format and used to
understand the progression of cells during the differentiation process. Not only can this data be
useful in understanding cell lineages but, by examining the transcriptomes of intermediate cells,
hypotheses regarding epistasis and regulatory networks can also be generated.

2.1.4 Modern RNA seq technologies
Today several modern technologies have matured to compete in the scRNA-seq space. These
technologies are largely differentiated by two factors: how they separate bulk tissues and mixed
cultures into single cells and how RNA species from each cell are tagged and identified. In the
following section we will go through the main high-throughput technologies in the single cell
sequencing space and discuss their advantages, applications, and challenges.

Drop-seq was one of the earliest high-throughput scRNA-seq technologies and set the stage for
future high-throughput solutions (Macosko et al., 2015). In Drop-seq, individual cells and beads
with oligonucleotides attached are sorted into an aqueous droplet surrounded by oil using a
microfluidic setup. These beads are known as ‘‘single-cell transcriptomes attached to
microparticles’’ or STAMPs for short. Each oligo on the STAMP contains a PCR priming region,
unique barcode corresponding to the captured cell, unique molecular identifier, and a poly-A
capture sequence. Although occasionally more than one STAMP or cell will end up in the same
droplet, the flow rate of the microfluidic device is adjusted so that statistically most droplets will
have one STAMP and cell, one of either, or remain empty. Upon droplet formation each cell is
lysed in its own aqueous environment and poly-A tailed RNA hybridizes with the poly-A capture
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sequence of the STAMP. Droplets are then broken and reverse transcription with template
switching is preformed, creating DNA sequences on the STAMP that contain the captured RNA
sequence, barcode, and a UMI. STAMPs are then aliquoted and used as PCR templates to create
libraries for next generations sequencing. Using this method, hundreds of thousands of cells can
be barcoded in a scRNA-seq experiment (Saunders et al., 2018).

A major drawback of Drop-seq was that most droplets contain either nothing, one bead or one
cell. Droplets must be loaded with beads or cells at a low concentration to ensure that
statistically few end up with doublets of either. As creating droplets is a linear process, these
empty droplets waste both time and materials. Not only does this make scalability past several
hundred thousand cells impractical, but it also becomes problematic when collecting as many
cells as possible from a limited sample is necessary. The Chromium system by 10x genomics is a
commercial endeavor that set out to solve this problem and improve droplet based scRNA-seq.
The system is very similar to Drop-seq in that it consists of encapsulating cells and barcoded
beads in an oil emulsion to tag cellular RNAs. However, the Chromium system has made several
improvements over the original technology. Chromium microfluidic devices consist of multiple
channels which parallelize the process, allowing for higher throughput (Zheng et al., 2017). In
addition, the devices and beads have been optimized so that greater than 80% of the droplets
contain a single bead. This greatly increases the efficiency of the system as beads no longer need
to be loaded at a limiting dilution. Unlike Drop-seq, the system uses gel-based beads that
dissolve and release their oligonucleotides for poly A capture and reverse transcription. The
combined bead and cell oil droplet is known as a “Gel bead in Emulsion” or GEM. Another
advantage over Drop-seq is that the gel-based beads allow for reverse transcription to take place
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within the droplet, reducing chances of cross contamination of barcodes between cells. After the
initial of reverse transcription and template switching (first strand synthesis) cDNA is generated
using primers specific to the template switching oligo and the P7 sequencing adaptors. Next the
cDNA is amplified, sheered, and P5 adaptors and sample indices are added to the finished library
for sequencing. These improvements have greatly increased the efficiency of microfluidic-based
scRNA-seq experiments.

In addition to the substantial improvements seen in microfluidic bead-based solutions, platebased solutions have also made major strides in efficiency and practicality. The combinatorial
indexing strategies such as SPLiT-seq have the potential to generate millions of barcoded cells for
scRNA-seq experiments using plates (Rosenberg et al., 2018). In this method, cells are fixed and
permeabilized (or nuclei are extracted), placed into 96 or 384 well plates with barcoded poly-T
capture sequences and reverse transcription is performed. This method differs from traditional
well plating by limiting dilution in that several to a dozen cells are added to each well at one time
and all cells in each well receive the same barcode. Cells are then removed from the wells,
combined, and re-plated into additional plates for a second round of barcoding. These secondary
plates contain primers with common sequences that prime off common sequences attached in
the first round of barcoding. Thus, each cell contains one of 96 (or 384) random barcodes from
the first round and another random barcode from the second round making the chances of two
cells having the same barcode unlikely. A third round of barcoding can also be applied. Finally,
cells are batched, and cDNA is amplified using standard library preparation techniques. Using this
method, millions of cells with unique barcodes can be generated for next generation scRNA-seq
experiments in a relatively short amount of time.
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2.1.5 Limitations of current scRNA-seq methods
The separation and isolation of single cells from complex tissues is one of the most challenging
problems facing modern scRNA-seq experiments. To date, all major single cell technologies rely
on the preparation of a relatively uniform population of single cells (or nuclei) before barcoding
can be performed. Complex tissues cannot be processed whole and differences in cell size can
affect microfluidics. Separation techniques can also damage cells with more complex
morphologies. For example, neurons have long processes that contain specific RNA that is
transported to neuronal junctions and glia such as oligodendrocytes, and astrocytes are
intricately attached to neuronal cells. Disruption of these cell types to create single cell
suspensions can sheer off processes and other extensions of cell bodies leading to loss of RNA
that may be critical for proper scRNA-seq data analysis. Differentiation steps and new terminal
cell types may be missed entirely due to this incomplete picture.

Cellular debris from myelin sheaths protecting the axon and neuropil are also a major
confounding factor and account for the majority of material in a sample after isolation (Ho et al.,
2018). Several protocols to further filter intact cell bodies from cellular debris have been
developed, however these add additional cost and time to experiments and result in loss of
usable samples. This is particularly a problem in highly diverse tissues with rare cell types such as
the brain and other tissues where samples may be limited as loss of cells may lead us to missing
lowly abundant but important cell types.
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Further, cellular dissociation protocols may confound data across experiments with different
dissociation conditions, favoring the intact isolation of some cell types over others. One study
found that cell type composition varied greatly depending on what temperature the dissociation
was performed at (Denisenko et al., 2020). The same study showed that cryopreservation of cells
vs immediate processing had a large effect on cell type composition (although notably methanol
fixation was comparable to fresh cells). This could be particularly problematic in animal studies
where tissues are frequently cryopreserved prior to processing for scRNA-seq. This could also be
a major problem for single-cell cancer studies as, given the highly heterogeneous nature of
tumors, biased losses due to single-cell separation protocols may miss critical information on
tumor progression, stem-like populations, or metastasis. Nuclei sorting has sought to overcome
this problem by isolating the nuclei of cells for scRNA-seq instead of cell bodies, however an
analysis of nuclei extraction has shown that strong biases exist in what cell types are recovered
when compared to fresh tissue (Denisenko et al., 2020).

While modern scRNA-seq technologies have come a long way in improving throughput, technical
challenges remain which need to be overcome to gain a complete picture of transcriptomics at
the single cell level in all tissues. Namely, separation techniques are a major hurdle for all
modern scRNA-seq protocols, and debris from complex tissues limit whole cell yield. The ideal
scRNA-seq technology would not require single cell separation prior to barcoding cells. This
would remove the bias and sample loss currently seen in separation and nuclei extraction
protocols. A technology that could provide stable barcoding of transcripts within cells, prior to
RNA extraction, would remove many of these limitations. Such a technology would also reduce
the possibility of doublets (tagging two cells with the same bead) and cross contamination of
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free RNA when oil droplets are broken in microfluidic setups. The ability to harvest RNA directly
from fresh tissue would also avoid the need for labs to purchase expensive microfluidic
equipment or specialized plates and reagents and improve accessibility of scRNA-seq
experiments. In short, removing cell separation as a prerequisite for scRNA-seq by adding a
method of in-vivo RNA barcoding would be a significant advancement in the field.

2.1.6 Trans-splicing as a method for modifying endogenous pre-RNAs
To achieve a method of barcoding endogenous cellular RNAs for scRNA-seq experiments, we
require the ability to add additional sequence information to mRNA while preserving enough of
the of the original transcript to map back to the transcriptome. One technology that has seen
success in this area is known as trans-splicing. Normal splicing is the process by which cells
process pre-mRNAs to remove introns and create alternative transcript. Over 95% of mammalian
transcripts that express proteins undergo splicing for proper protein expression (Bonnal et al.,
2020). For splicing to occur, splice sites within the pre-RNA must be properly defined. Splice
donor sites typically require a GT dinucleotide at their 3 prime ends to serve as a signal for the
U1 snRNP complex to bind. Splice acceptor sites consist of an adenine branch point,
polypyrimidine and AG dinucleotide where U2 snRNP, U2AF65, and U2AF35 bind. Splicing is also
modulated by factors known as intronic or exonic splice enhancers and silencers which are
motifs that bind splicing regulatory factors. In normal splicing these signals combine to recruit
the rest of the spliceosome, removing the intron and stitching ends of the exons together to
create mRNA (Wang et al., 2015). We refer to this type of splicing as cis-splicing as all of the
reactions take place on the same RNA molecule.
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Trans-splicing is a phenomenon where a donor exon from one transcript joins with the acceptor
exon from a different transcript, creating a chimeric fusion of the original RNAs. This
phenomenon occurs naturally between pre-mRNAs within the transcriptome and has generally
been seen as errors in splicing, however there is a growing body of evidence that trans-splicing
functions to increase diversity in the proteome and provide novel regulatory mechanisms for
gene expression (Lei et al., 2016). Trans-splicing has also been used in gene therapy to replace
defective segments of transcripts with corrected exons. This technology is known as
Spliceosome-mediated RNA trans-splicing or SMaRT (Wally et al., 2012). Endogenous pre-RNA
can be targeted for trans-splicing by expressing an active splice acceptor or donor site fused with
a sequence that base pairs with segments of the native RNA. Collectively this molecule is known
as a pre-mRNA targeting molecule or RTM (also sometimes seen as PTM in the literature).
Binding of an RTM to pre-RNA increases local concentration of the trans-splicing molecule’s
splice site and the binding domain may also bind regulatory elements weakening the native
splice site. This results in a percentage of the native targeted exon being replaced with transspliced RNA.

SMaRT technology has been evaluated to treat numerous diseases including cystic fibrosis ,
hemophilia A, hyper-IgM X-linked immunodeficiency, spinal muscular atrophy, severe combined
immune deficiency, epidermolysis bullosa and several muscular dystrophy diseases including
dysferlinopathies, titinopathies (Monjaret et al., 2014) and Duchenne muscular dystrophy. This
strategy has several advantages over simply introducing cDNA into cells directly. Since RTMs only
need to correct a portion of the targeted pre-mRNA, their payload is much smaller, allowing
them to fit within the size constraints of delivery vectors such as adenovirus. Another advantage
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is that correcting endogenous pre-mRNA converts mutant RNA to wildtype, simultaneously
increasing the amount of wildtype protein while reducing the expression of dominant negative
alleles.

While the many advantages of SMaRT technology make it appealing as a therapeutic, there are
also downsides. Off target effects of trans-splicing molecules could be potentially dangerous if
fusions to the wrong pre-mRNAs were made. One could envision many scenarios where creating
hybrids of binding and activation domains from different proteins could wreak regulatory havoc
on an organism. Thus, new RTMs need be carefully evaluated, not just for trans-splicing
efficiency but also for specificity of the binding domain. In one study researchers sought to
design a PTM to treat somatic mutations of RET, a gene implicated in medullary thyroid
carcinoma. When clones were subjected to 5’ RACE analysis they observed a wide range of nonspecific, chimerically spliced mRNAs, with none of the 20 clones analyzed containing fusions RET.
Further, when amplifying RNA fusions specific to RET, they observed that use of the 3’SS alone
resulted in trans-splicing efficiencies only slightly less than an RTM containing both the RET
targeting binding domain and 3’SS acceptor. This suggested that the 3’SS acceptor on its own
was highly promiscuous, and could trans-splice a wide array of genes without a binding domain
(Kikumori et al., 2001). While this is a major drawback for targeted trans-splicing, the nonspecific nature of this 3’SS acceptor could potentially make it ideal for randomly attaching
specific pieces of RNA to a wide array of transcripts, such as in RNA barcoding applications.

2.1.7 Internal RNA Identifier Sequencing (IRIS)
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We hypothesized that promiscuous trans-splicing could be used to add barcodes to a subset of
endogenous RNA allowing them to be tagged and traced back to individual cells for single-cell
sequencing applications. Here we present IRIS: Internal RNA Identifier Sequencing, a high
throughput method for single cell sequencing from bulk RNA tissue preps. IRIS makes use of a
simple, low-cost protocol that can be completed in a single day, without specialized equipment,
and has no limit on throughput. The IRIS construct consists of a promiscuous trans-splicing
acceptor sequence, from adenovirus major late transcript intron 1, a 16 base-pair randomized
barcode and a priming region for first strand synthesis and amplification, driven by a CMV
promoter (Figure 2.1). This construct is cloned into a lentiviral packaging vector and a complex
library of uniquely barcoded trans-splicing elements is generated with each virion containing a
different barcode. The virus is then delivered at a low MOI so that each cell receives on average
one copy of the virus. For cell culture applications the construct also contains a selectable
marker such as GFP or puromycin (in-vitro) so that only cells that were transduced with the virus
can be selected if desired. Once integrated, the IRIS 3’SS competes with endogenous splice
acceptor exons and trans-splices into a portion of the cell’s endogenous RNA, attaching unique
cell barcodes into these transcripts. Cells or tissues are then harvested and processed without
the need for cellular separation, bulk RNA is extracted. Tagged RNAs are recovered by reverse
transcription specific to the barcoded trans-spliced IRIS exon and cDNA is generated. Since
endogenous RNA does not contain the IRIS first strand synthesis priming site, this RNA is not
amplified in the reaction. A restriction digest specific to unspliced IRIS RNA is also included to
remove IRIS transcript that did not trans-splice. The cDNA library is then tagmented and
amplified using primers specific to IRIS one tagmentation primer such that only the 3’ IRIS
barcoded ends of trans-spliced endogenous RNA are captured. This library is then sequenced via
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next generation Illumina sequencing and RNAs are mapped back to genes in the human genome
while barcodes are used to sort which cells reads originated from.

2.2 Results
2.2.1 Evaluating a single barcode IRIS construct
To test whether promiscuous 3’ trans-splicing could be used to barcode endogenous RNA, we
cloned a 3’ splicing signal sequence (3’SS) derived from adenovirus major late transcript intron 1,
consisting of a canonical AG splice site downstream of a polypyrimidine tract, into lentiviral
transfer plasmid and drove it’s expression via a CMV promoter (Figure 2.2A). Directly following
the 3’SS, we cloned a six base pair IRIS identifier sequence known as the IRIS pre-barcode
sequence (PBS), a 16 base pair barcode, and a primer binding site followed by a WPRE sequence.
Collectively this sequence was called an internal RNA identifier sequence or IRIS. The IRIS
construct was then packaged into a third-generation lentivirus and titered via flow cytometry on
GFP. HEK293T cells were then exposed to the virus at an MOI of 0.3 to ensure most transduced
cells received only one integrated copy of the virus. After one week the cells were sorted via flow
cytometry, bulk RNA was extracted and selectively reverse transcribed via the IRIS specific
primer and cDNA was sequenced via next generation sequencing.

Of the 714,069 reads captured, 294,105, or 41% of the reads contained the IRIS PBS and barcode
(Figure 2.2B). Only reads containing an exact match to the IRIS PBS and barcode were considered
for this analysis, however it is likely we could have obtained more reads by loosening this
restriction to allow for a greater hamming distance. Of the 294,105 IRIS containing reads, 16%
mapped back to the genome as endogenous transcript trans-spliced with an IRIS barcode, 25%
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were identified as un-spliced IRIS product, and 59% were identified as IRIS having cis-spliced with
product from the lentivirus integration product (Figure 2.2C). Analysis of the 59% non-IRIS reads
showed that most reads mapped back to the human genome but did not contain IRIS transsplicing events. It is likely that due to the low rate of promiscuous IRIS trans-splicing and large
diversity of sequences in the human transcriptome, non-specific product with partial homology
to the first strand synthesis primer was amplified during creation of the cDNA.

Over-all, endogenous RNA trans-spliced with IRIS represented 6.4% of total reads. Analysis of the
reads themselves confirmed that they consisted of endogenous human RNA in place of the IRIS
3’SS, followed by the IRIS PBS and barcode. The motif “AG” serves as the canonical splice site for
3’ splice acceptor RNA. As expected, fusion of the IRIS PBS and endogenous RNA took place at
this AG junction, replacing the entire upstream IRIS 3’SS with endogenous RNA. Given these
results we conclude that the IRIS construct is trans-splicing successfully, capable of attaching a
barcode to endogenous RNA, and able to be detected by next generation sequencing.

2.2.2 Most IRIS trans-splicing events occur at GT junctions
In humans, most 5’ splice sites are defined by highly a conserved dinucleotide “GU” base pair
which is required for splice site recognition. A secondary minor class of introns is also known and
uses an “AU” dinucleotide instead and mutation of either of these dinucleotides has been shown
to eliminate normal splicing (Patel & Steitz, 2003). We hypothesized that if trans-splicing were
occurring in the IRIS construct, most splicing events would occur at either of these dinucleotides
(Figure 2.3A). To determine if this was the case, we mapped successful IRIS splicing with
endogenous RNA to the human genome and analyzed the frequency of dinucleotides
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downstream of the endogenous sequence (Figure 2.3B). We found that 63% of human genome
mappable IRIS trans-splicing events occurred at the predicted “GU” dinucleotide junctions, with
the second largest dinucleotide sequence being “AU” occurring at a frequency of 23% (Figure
3B). The remaining 14% of splice events were distributed across other dinucleotides at low
frequencies. These results lend support to the hypothesis that IRIS is trans-splicing via canonical
splicing machinery at expected splice junctions.

2.2.3 Estimating molecular detection efficiency as a function of positive control
abundance
Next, we wanted to estimate the efficiency of our protocol at detecting trans-splicing events in
cells. To do this we cloned the sequence for the fluorescent marker TD-tomato in place of the
IRIS 3’SS to simulate a successful splicing event (Figure 2.4A). This IRIS variant was confirmed to
be TD-tomato positive when viewed under a fluorescent microscope. We also cloned a variant of
IRIS where the 3’SS was scrambled and verified to be non-functional through transduction and
next generation sequencing (Figure 2.4B). We then transduced separate populations of HEK293t
cells with each virus at a low MOI (0.3) and sorted for cells that transduced successfully via GFP.
To simulate varying levels of splicing efficiency, 50,000 cells comprising varying ratios of TD-IRIS
and Scrambled-IRIS were mixed and run through a standard IRIS protocol for cDNA generation
and next-generation sequencing (Figure 2.4C). 100% TD-IRIS to 0% Scrambled cells represented a
scenario where all IRIS produced by the CMV promotor would have spliced successfully into
endogenous pre-RNA transcript and 0% TD-IRIS to 100% Scrambled cells represented a scenario
where no IRIS trans splicing events occurred. A step is included in the standard IRIS protocol to
eliminate un-spliced reads by cleavage at a restriction site that is spliced out upon successful
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trans-splicing events. This site was also included in the scrambled IRIS but not present in the TDIRIS mock trans-splicing construct. Thus, we expect the majority of IRIS product amplified to
consist of TD-IRIS.

Upon sequencing, no mock IRIS trans-spliced reads could be detected in the 100% scrambled
control. In the 5% TD-IRIS sample, our lowest ratio containing TD-IRIS, only 0.3% of the total
reads recovered were successful mock TD trans splicing events, whereas in the 100% TD-IRIS
sample, 85% of total reads were observed to be IRIS reads (Figure 4C). At 30% TD-IRIS, 70% of
recovered reads were mock-splicing events, at 10% TD-IRIS, 56% of reads were mock-splicing
events, at 3% TD-IRIS, 31% of reads were mock-splicing events and at 1% TD-IRIS, 13% of
recovered reads were mock-splicing IRIS.

The results of this experiment show us that high levels of successful trans-splicing can be
detected efficiently by our protocol, however our ability to amplify IRIS reads from non-specific
background amplification becomes limiting as trans-splicing efficiency goes down. We were also
able to use this data to estimate the trans-splicing efficiency of our previous single barcode
experiment. By fitting the data to a logarithmic expression, we came up with the formula y =
0.147ln(x) + 0.8595 (R2 = 0.98) where “y” is the expected percentage of sequenced IRIS reads
and “x” is the efficiency of successful IRIS trans-splicing to endogenous RNA. Using this we are
able to derive an equation x = e^((y – 0.8595) / 0.147) which predicts the rate of trans-splicing (x)
in a simple IRIS experiment from the percentage of recovered IRIS reads (y) in this protocol.
Plugging in 6.4% as the total percentage of recovered IRIS reads from the single barcode
experiment, we estimate that this experiment had a trans-splicing efficiency of around 0.45%.
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An additional observation we were able to make from this data was that total reads sequenced
varied greatly depending on the percentage of TD-IRIS present in the 50,000 cells, despite all
samples undergoing the same protocol and being normalized for concentration before being
loaded equally onto the sequencer. We noted that a Pearson correlation test showed that the
percentage of TD-IRIS was highly correlated to the number of reads obtained from the
sequencing run (R = 0.89, P <= .05). To investigate this further, final amplified material from the
lowest ratio of TD-IRIS : Scrambled IRIS was TA cloned into bacteria and sent for sanger
sequencing. We observed that these sequences largely consisted of miss-amplified endogenous
RNA with similarity to primers used in the protocol but lacking any IRIS components. Further,
these sequences did not contain all the required adapters needed to bind to a flow cell for
sequencing. We hypothesize that, given the large diversity of background sequences in each
sample, non-specific background material was amplified in samples with low amounts of IRIStrans-splicing. Over all these results show us that the efficiency of our protocol to detect transsplicing events is greatly limited by the abundance of successfully trans-spliced sequences.

2.2.4 Analysis of a 2.5 million barcode IRIS library
Next, we wanted to determine if IRIS could be used to distinguish RNA from individual cells. To
do this we constructed an IRIS lentiviral library consisting of over 2.5 million unique barcodes and
transduced a population of HEK293T cells at low MOI (0.3) to ensure that the majority of
successfully transduced cells received only one barcode. GFP was used as a marker for successful
transduction events. Of the 1 million cells transduced, flow cytometry was used to collect 10,000
GFP positive cells. These cells were then lysed for bulk RNA which was then put through our
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standard IRIS protocol and sequenced via next generation sequencing. Of the total of 26,284,131
reads that we sequenced, 18,467,378 (70%) were identified as IRIS reads with the remaining
7,816,753 reads being mis-amplification or not meeting our criteria of 0 hamming distance to
the 6 base pair IRIS PBS (Figure 2.5A). IRIS reads were analyzed and broken down into the
following categories: successful trans-splicing events, un-spliced IRIS, and cis-spliced reads
(Figure 2.5B). IRIS reads which successfully trans-spliced into endogenous RNA made up,
1,847,336 or 10% of total IRIS reads, un-spliced IRIS made up 1,167,746 or 6% of IRIS reads and
cis-spliced reads which spliced into a portion of the lentiviral transcript accounted for 15,323,852
or 84% of total IRIS reads. The 1,847,336 reads with trans-splicing information that would be of
potential use in single-cell RNA seq experiments made up 7% of the total reads.

Next, we sought to analyze the number of barcodes recovered in the experiment. Using a
custom python script (cascade.py), we ranked barcodes by read count and collapsed barcodes
from the top down using a hamming distance cutoff of 2. To make the algorithm efficient and
eliminate low read count value barcodes, the program employed a cumulative distribution
function (CDF) plot, plotting cumulative reads against barcodes ranked by read count. By
calculating the slope of the CDF plot at each point we are able to determine when the curve
began to flatten, an indication that including additional barcodes would provide diminishing
returns in terms of read count. We therefore eliminated all barcodes beyond a slope of 10. Our
cascade algorithm collapsed the total barcode count down from 51,449 unique cell barcodes to
8,224 unique cell barcodes, or 82% of the 10,000 barcodes expected, with each barcode
representing reads from a single cell.
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Collapsing barcodes allowed us to analyze per cell trans-splicing statistics, giving us deeper
insight into IRIS trans-splicing. For each barcode we calculated read count, genetically mapped
reads (trans-splicing events), cis-spliced reads, unique trans-splicing insertion events, and unique
trans-spliced genes. Unique splicing events were defined as trans-splicing events that occurred
at the same genomic locus, while unique genes were defined as any genes that we observed to
have a trans-splicing event within the cell. Of the 8,224 unique cells barcodes, we found that
4,393 (53%) contained reads that mapped back to genes, with a total of 2,948 genes
represented. However, despite the large number of genes captured, most cells did not represent
this diversity. Only 184 (4.1%) of the barcoded cells containing trans-spliced mapped reads had
10 or more genes represented. The distribution of gene diversity across cell barcodes was highly
skewed with the top barcode containing 1037 unique genes and most cells containing 1 or fewer
barcodes (Figure 2.5C).

One interpretation is that we did not sequence deeply enough to capture representative single
barcode trans-splicing data as 1,294 (68%) of the 1,908 cells with only 1 gene represented had
10 or fewer reads. However, given that only 1,866,728 of the 26,284,131 reads sequenced
(7.1%) contained gene mappable trans-spliced reads, sequencing deeply enough to obtain useful
data for a single cell RNA seq clustering experiment would be cost prohibitive at current transsplicing efficiencies. It is also possible that deeper sequencing would not yield many additional
trans-splicing events beyond what we have observed and that some cells are more prone to
trans-splicing events than others. In either case, improving the efficiency and consistency of
trans-splicing and reducing sequencing noise are both crucial to making IRIS a usable technology
for single cell clustering.
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2.2.5 U1 snRNA IRIS fusion to localize IRIS to 5’ splice sites
To improve trans-splicing efficiency, we fused IRIS to a portion within the 5’ end of the U1
spliceosomal RNA (U1 snRNA) and expressed it in a lentiviral transfer plasmid behind a standard
U1 promotor. In splicing, U1 snRNA base-pairs with a 5’ splice junction and recruits U1 small
nuclear riboprotein (U1 snRNP) to initiate splicing. We hypothesized that by combining IRIS with
U1 snRNA, we could localize IRIS to splice donor sites and improve trans-splicing efficiency
(Figure 2.6A). A single barcode version of the U1 5’ IRIS fusion, herein known as U15P-IRIS was
created and HEK293t cells were transduced using a standard IRIS protocol. In the single barcode
U15P-IRIS experiment we sequenced a total of 101,173 reads. Of these reads, 29,496 (29%)
contained an IRIS PBS and the expected “TGCGTGTCGACCTTAA” barcode (Figure 2.6B). To better
gain an understanding of the performance of the U15P IRIS construct we broke down the
population of reads with IRIS sequences into sub-categories (Figure 2.6C). 7,696 (26%) of IRIS
reads were true trans-splicing events, containing sequences that mapped back to human genes,
3,739 (13%) were un-spliced IRIS that survived the selective restriction digest and were
amplified, and 18,061 (61%) of reads were cis-splicing events that mapped back to upstream
sequences in the integrated lentivirus.

Total useable trans-splicing reads in the U15P construct made up 7.6% of all reads, compared to
6.4% and 7% in the single barcode CMV-IRIS and barcoded CMV-IRIS experiments, respectively.
While fusing IRIS to the 5’ of a U1 snRNA did not seem to harm trans-splicing efficiency, it also
did not seem to markedly improve trans-splicing rates. One explanation may be that U1 snRNA
fused with IRIS no longer functions in the spliceosome and thus does not localize to 5’ splice sites
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as we had hoped. Further experiments testing whether the modified U1 snRNA still interacts
with 5’ splice sites would need to be performed to test this hypothesis.

2.2.6 Analysis of cis-splicing events across IRIS constructs
In all IRIS experiments so far, cis-spliced reads were a large portion of total IRIS reads. We
posited that eliminating cis-spliced IRIS would reduce the number of non-usable total reads we
sequenced, allowing us to sequence more mappable trans-spliced IRIS reads. To determine how
cis-splicing events were occurring, we mapped cis-splicing IRIS reads from a CMV-IRIS (Figure
2.7A) and a U15P-IRIS (Figure 2.8A) experiment to locations on their respective lentiviral
integration products. For cis-splicing to occur, RNA transcript including the IRIS splice site would
have to be made in the 5’ to 3’ direction. This was supported by the observation that nearly all
cis-splicing occurred upstream of the promotor driving IRIS in both constructs, but no cis-splicing
occurred downstream.

In CMV-IRIS, we observed that cis-splicing tended to occur around the 5’ UTR and central
polypurine tract (cPPT) of the lentivirus intermediate transcript, and that the most active region
of cis-splicing occurred just downstream of the minimal CMV promotor driving the GFP marker
(Figure 2.7A). These three regions made up the majority of cis-splicing in a standard IRIS
experiment with some additional cis-splicing clustering within and around the CMV promotor
driving IRIS.

Analysis of the U15P-IRIS experiment found that most cis-splicing events clustered around the
minimal promotor driving CMV and within the U1 promotor driving IRIS (Figure 2.8A). One key
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difference between the U15P-IRIS and CMV-IRIS construct was that in U15P-IRIS the direction of
the region with the IRIS and GFP promotors was flipped. This accounts for the difference in cissplicing hotspots compared to CMV-IRIS.

2.2.7 Strategies to eliminate IRIS cis-splicing
The above analysis illuminated cis-splicing hotspots and confirmed that cis-splicing must be
taking place in the 5’ to 3’ direction on transcript containing IRIS, as nearly all cis-splicing
occurred upstream of the IRIS start site regardless of promotor direction. However, we still do
not know the exact mechanism by which these transcripts containing IRIS plus regions of the
lentiviral insertion are being transcribed.

During transduction, lentivirus produces an RNA intermediate of the sequence to be integrated
into the genome as DNA. Our initial hypothesis was that IRIS was trans-splicing into this
intermediate. However, if this were the case then we would never see cells with both cis-splicing
and trans-splicing when examining events at a per-barcode level as cells with cis-splicing events
occurring during the intermediate RNA phase would have spliced out their own IRIS sites prior to
integration. As we observe many cells with both cis-splicing and trans-splicing within the same
cell barcode we can reject this hypothesis. Another hypothesis was that what we interpreted as
cis-splicing was actually IRIS trans-splicing into long transcript produced by the minimal CMV
promotor driving GFP. However, we can also reject this hypothesis as all cis-splicing events
examined occur on the opposite strand and in the wrong direction for this to be possible. Thus,
we know that IRIS cis-splicing must be a result of integrated lentiviral DNA being transcribed
within the genome beginning upstream of the promotor designed to drive IRIS.
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We hypothesized two ways this transcript could be produced. The first possibility was that
external promotors were driving production of the lentiviral integration. Integration behind an
active promotor may drive the full integration transcript to be produced allowing for cis-splicing
anywhere along the transcript upstream from IRIS (Figure 2.9A). If this were the case, restriction
digest at a site near the 5’ end of the integrated product after several rounds of second strand
synthesis should eliminate cis-splicing from the pool of subsequently amplified sequencing
products. Another possibility was that cis-spliceable transcript was created via basal levels of
transcription within lentiviral integration DNA (Figure 2.9B). If this were the case, we expect a
restriction digest at the 5’ end of the lentiviral integration product to only remove cis-splicing in
that region, as it would only affect full length lentivirus transcript.

2.2.8 Cis-splicing is partly caused by full length lentiviral integration transcript
To test if cis-splicing was occurring due to full length lentiviral transcript produced by an
upstream genomic promotor we identified a Sfo1 site near the 5’ end of the lentiviral integration
sequence in our IRIS-CMV construct. We performed a standard IRIS experiment and after three
rounds of second strand synthesis we digested the product with Sfo1. This ensured that any DNA
containing the Spf1 site would no longer be able to amplify as it would be missing priming sites
at the 5’ end. We then preformed a cis-splicing analysis on this product and mapped cis-splice
sites back to the lentiviral transfer plasmid payload.

We observed a marked reduction in cis-splicing across the transcript (Figure 2.7B) with all cissplicing near the Sfo1 site eliminated from the digested sample entirely. We also observed that
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many cis-splicing sites throughout the lentiviral transcript were removed entirely indicating that
these sites were also a product of the full-length transcript. However, we did not observe
complete elimination of all cis-splicing sites. Three of the previously mentioned cis-splicing
hotspots remained active including the cPPT site, a site within GFP and cis-splicing near the IRISCMV promotor.

We interpret these results to mean that while a substantial portion of cis-splicing was due to full
length lentiviral transcript being transcribed within the genome, not all cis-splicing could be
accounted for by this hypothesis. Thus, we can conclude that at least some cis-splicing is due to
basal transcription occurring within the integrated lentiviral DNA as these downstream sites
were not eliminated by Sfo1 digestion, so could not have been produced by full length lentiviral
integration transcript. This makes eliminating cis-splicing in the IRIS-CMV construct particularly
difficult as we now know that whether a reaction site is within the cis-spliced product is
dependent not only on where the cis-splicing occurs but also on the start site of the original
transcript.

2.2.9 Eliminating basal transcription cis-splicing within U15P-IRIS
In the case of U15P-IRIS, the majority of cis-splicing clustered within two major sites both within
400 bases of each-other; around the minimal CMV promotor driving GFP and within the U1
promotor driving IRIS itself. We hypothesized that the restriction digest of BsmBI site just
upstream of the CMV promotor would eliminate the major cis-spliced transcript products from
both sites and thus most of the cis-splicing observed in our reads (Figure 2.8B). Upon digesting
the second strand synthesis product with BsmBI after three rounds of amplification, and then
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continuing with additional amplification rounds, we observed a large reduction in cis-spliced
reads with all cis-splicing eliminated from the U1 promotor region and the most abundant cissplicing product eliminated from the minimal CMV region.

2.2.10 Analysis of the barcoded U15P IRIS library
Next, we sought to apply our success with cis-splicing reduction with a barcoded IRIS library. To
do this we created a 16N barcoded version of U15P IRIS construct and added a BsmBI digestion
to our standard protocol. As expected, few differences, were observed between the barcoded
U15P IRIS library with BsmBI digestion and a typical U15P IRIS run with respect to overall IRIS
reads. Out of 78,583 total reads sequenced, 62% contained the IRIS PBS (Figure 2.10A).
However, a major improvement was seen in breakdown of these reads regarding the number of
transcripts recovered with usable trans-splicing events. Of the reads that contained the IRIS PBS,
86% were mapped trans-splicing events, 1% unsliced IRIS and only 13% cis-spliced reads
compared to the previous experiment performed without BsmBI, which consisted of 26%
mapped trans-splicing events, 13% unsliced IRIS and 61% cis-spliced reads (Figure 2.10B).

An interesting observation was that the proportion of un-spliced reads within the total
population of IRIS reads decreased in the BsmBI digested experiment. We would have expected
this population to have increased as a percentage of total IRIS reads as BsmBI digestion should
have only affected the cis-spliced population. Unspliced IRIS reads are identified by their
retained IRIS 3’ splice sites. These results indicate that a portion of un-spliced IRIS reads were not
produced by the U1 promotor but instead by upstream basal activity and that these were
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intermediates to cis-splicing that had not spliced yet. Thus, by digesting with BsmBI we also
eliminated this mis-categorized group of non-trans-spliced reads.

Despite this improved recovery rate of trans-spliced IRIS reads, we did not see much of a shift in
distribution of reads across barcodes (Figure 2.10A). While the zero-splicing category was
brought down to only 10% of barcodes, only 3% of the cells contained over 5 unique splicing
events. Deeper sequencing with this construct and protocol would be needed to see if additional
splicing events could be observed in these cells.

2.2.11 Enrichment of ESS but not ESEs in IRIS barcodes
So far in our experiments we have seen that some cells have large numbers of trans-splicing
events, while others have few to zero events. We hypothesized that our barcodes may have
been acting as splicing regulatory motifs that affected splicing efficiency. Exonic splice regulators
(ESRs) are short sequences in exons that serve as motifs that either enhance or suppress splicing.
These sequences recruit regulatory proteins which interact with the spliceosome and help define
splice site boundaries (Cartegni et al., 2002). Two main classes of ESRs exist, exonic splice
enhancers (ESEs) which encourage splicing, and exonic splice silencers (ESSs) which, suppress
splicing. The presence and activity of these regulatory regions modulates alterative splicing to
create alternate transcripts from genes. Given the proximity of our barcodes to the IRIS 3’SS, we
hypothesized that some of barcodes may contain sequences acting as ESRs. To test for this, we
used previously published lists of ESEs and ESRs and scanned our barcodes for their presence
(Stadler et al., 2006). We reasoned that barcodes with splicing events (cis or trans) would be
enriched for known ESEs, and that barcodes that had no splicing events would be enriched for
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ESSs. Using data from our barcoded IRIS CMV experiment we separated barcodes into two
categories, spliced and un-spliced, and used a custom python script to identify the number of
known ESEs and ESS occurred in each barcode sequence. We then plotted the average number
of ESEs or ESSs we observed in each category and used a Mann Whitney U test to determine if
the enrichment we saw between spliced and un-spliced barcodes was significant. We observed
no significant enrichment in ESEs between barcodes with splicing events and barcodes without
splicing events. Spliced barcodes contained an average of 1.03 ESEs per 16 base barcode, while
un-spliced barcodes contained an average of 1.09 ESEs (NS) (Figure 2.11A). In contrast ESSs saw
a significant (P <= 0.001) enrichment in unspliced barcodes vs barcodes with splicing events
(Figure 2.11B). Unspliced barcodes contained an average of 0.47 ESSs per 16 base sequence,
compared to only 0.32 ESSs per barcode in spliced sequences. This constitutes a 47% enrichment
in ESSs in unspliced barcodes compared to barcodes with trans or cis-splicing events.

2.2.12 Single gene IRIS trans-splicing amplification
While IRIS was developed as a method to barcode a variety of transcripts for scRNA-seq
experiments, the technology can also be used to amplify trans-splicing events in specific genes at
specific exons junctions. This could be useful for a variety of applications including searching for
RTMs that trans-splice efficiently into target locations. To test whether IRIS could be used to
amplify a single gene, our positive TD-IRIS control from our mock trans-splicing event was used
to transduce HEK293t cells and primers specific to TD-tomato and the 3’ priming site of IRIS were
used to amplify cDNA from extracted RNA. Gel amplification showed the expected 864 base pair
band and spike-in sequencing confirmed that this was our expected TD-tomato-IRIS fusion.
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2.3 Discussion
2.3.1 Analysis and conclusions
The ability to quickly process large amounts of cells for scRNA-seq experiments has been a major
milestone in genomics, leading to the discovery of numerous new cell types and a better
understanding of developmental biology. However, scalability of throughput and the need to
separate cells prior to barcoding remain limiting factors of the technology. Microfluidic
technologies have linear throughput, and do not scale with larger experiments. Sort based
algorithms do not suffer as much from this limitation, however they still require single cell
suspensions which can be difficult to obtain from complex tissues such as neurons, where the
majority of such suspensions is comprised of debris from supporting glial tissues (Ho et al.,
2018). While nuclei extraction avoids some of these issues, it has been shown to be biased, with
certain cell types represented well and others poorly represented or dropping out entirely
(Denisenko et al., 2020). A scalable, high-throughput scRNA-seq strategy that barcoded RNAs
within the cells themselves would obviate the need for single cell suspensions and be a valuable
and impactful advancement in the field.

In this section we presented IRIS, Internal RNA Identifier Sequencing, a technology to barcode
endogenous RNA within cells using a short, untargeted trans-splicing RNA. We have shown that
IRIS trans-spliced RNA can be selectively amplified from bulk RNA using a set of IRIS specific
primers, and that trans-spliced barcoded RNAs can be sequenced and their barcodes collapsed
so that RNAs can be assigned to their individual cells of origin. To validate the technology, we
preformed both single barcode IRIS experiments as well experiments with millions of
randomized barcodes. We used a lentiviral vector administered at a low MOI to HEK293t cells in
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tissue culture and were able to recover trans-splicing events from both the single and multiple
barcoded experiments. To analyze our data, we used a custom pipeline to collapse cell barcodes
into single cell data and map the endogenous portion of the trans-spliced reads back to genes in
the human genome. The strength of our pipeline and barcode collapsing algorithm, cascade.py,
was demonstrated in the multiple barcode experiment where we selected 10,000 IRIS expressing
cells and were able to recover 8,224 unique cell barcodes, or 82% of the 10,000 barcodes
expected. Most algorithms to collapse barcodes, such as those employed in UMItools (T. Smith
et al., 2017), require prior knowledge of the expected number of barcodes and collapse a similar
number of barcodes, whereas our algorithm was able to determine the correct number of
barcodes without any prior information. This is an important component of the technology as it
allows us to process RNA from samples such as bulk tissue preps, where the number of cells and
barcodes may not be known prior to sequencing.

Upon mapping IRIS trans-splicing events to genes and examining splice junctions, we were able
to determine where splicing occurred along the transcript. Examining the dinucleotides in the
genome just downstream of the mapped trans-spliced junction, we observed that most IRIS
splicing occurs at the expected, and highly conserved, GU or AU dinucleotides. This evidence
supports the hypothesis that IRIS splices via canonical spliceosome machinery at predicted splice
junctions. While most IRIS trans-splicing occurs at known splice junctions, splicing into other
locations within genes was also observed. One possibility is that these are bonified splice sites
that occur in nature to create novel transcripts. RT-PCR or PCR amplification and gel analysis
should be performed at these sites in non-IRIS samples to determine if this is the case. Another
possibility is that these are weakly defined splice sites which become active in the presence of
71

the IRIS 3’SS. In either case, a systematic analysis of splice site preferences would be of further
interest, as IRIS could be used to map out potential splicing locations that have not been
previously observed. This information would also be useful for understanding if IRIS has any
biases towards particular sequence motifs.

To ascertain the detection limit of the protocol we used to amplify and sequence IRIS, we
created a positive control consisting of a transcript for the fluorophore mCherry and the portion
of the IRIS construct that is fused to endogenous RNA upon trans-splicing. We mixed positive
control transduced cells in various ratios with IRIS with a scrambled splice site and sequenced
the samples. This mixing served as a proxy for transcript splicing efficiency. An important step in
our protocol was cutting unspliced IRIS product with an EcoRV restriction enzyme to eliminate it
from the amplification pool. This process was specific to unspliced IRIS, as spliced IRIS spliced out
the restriction site upon fusion with endogenous RNA and was included in the sequence
upstream of the scrambled 3’SS in the negative control. Interestingly, we observed that the ratio
of spliced to unspliced cells had a substantial effect on our ability to recover IRIS reads, with high
(100%) mock splicing efficiencies resulting in up to 85% IRIS reads and low mock splicing
efficiencies (0.3%) being comprised of only 5% IRIS reads and 95% uncut scrambled IRIS or
sequencing noise. The detection efficiency of the protocol dropped off steeply around 10% mock
splicing efficiency, recovering 56% IRIS reads. This data suggests that experiments that recover
few trans-spliced IRIS reads, as a percentage of the total sequencing, likely have low splicing
efficiencies. This also means that at lower trans-splicing efficiencies our ability to recover real
splicing events diminishes due to more competition with unspliced IRIS and amplification noise.
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Therefore, for IRIS to be sequencing efficient (and cost competitive) good noise reduction and
high levels of trans-splicing are necessary.

Trans-splicing efficiency remains one of the major hurdles needed for IRIS be used as a scRNAseq barcoding strategy. Using data from our mock trans-splicing experiment, we were able to fit
logarithmic expression and derive a formula to estimate trans-splicing efficiency from the
number of IRIS trans-splicing reads recovered as a percentage of total reads. In our initial
barcoded IRIS library experiment, 7% of the total reads we recovered were IRIS trans-splicing
events. Since the same protocol was used as in the positive control mixing experiment, we can
apply our splicing estimation formula and estimate that IRIS has a splicing efficiency of around
0.47%. This low splicing rate poses a practical problem for IRIS as an scRNA-seq technology, as
most of each run is composed of cis-splicing events and unspliced transcript. Thus, only a small
portion of each run is usable for scRNA-seq data. At this efficiency we estimated that IRIS transsplicing efficiency would need to improve about 10-fold in order to be cost competitive with
other scRNA-seq barcoding solutions. Alternatively, improved strategies to remove cis-splicing
and unspliced IRIS could be employed to increase the signal to noise ratio of the amplification
protocol.

One attempt we made to improve IRIS trans-splicing efficiency was to fuse IRIS with the
U1snRNA so that it would be localized to the U1 portion of the splicing complex. We
hypothesized that this would increase the local concentration of IRIS at the splice donor site and
improve the chances of trans-splicing with the IRIS splice acceptor. Unfortunately, we saw only a
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modest increase in trans-spliced reads recovered as a percentage of total reads, indicating little
to no improvement in splice efficiency in our barcoded U1 fused IRIS library.

We also sought to improve IRIS trans-splicing efficiency via exonic splicing regulatory motifs. An
interesting observation we made in our CMV driven IRIS experiments was that trans-splicing
reads were heavily skewed such that a handful of cells contained most trans-splicing events.
While one might first consider that these high trans-spliced cells are barcodes that have been
over-collapsed, this is mathematically unlikely given the hamming distance requirement of 2 and
the fact that these are 16N randomly generated barcodes. We hypothesized that these barcodes
contained exonic splicing enhancers (ESEs), which contributed to their enhanced trans-splicing
ability. However, upon examination, we found no enrichment in known ESEs between these cells
and other cells in the sample. Additionally, we tried making a single barcode library out of the
top cell, which contained over 1000 unique trans-splicing events, hypothesizing that this barcode
contained a novel ESE, however no improvements in trans-splicing efficiency were seen
compared to a typical splicing experiment. Thus, the most likely explanation is that this is a
stochastic effect seen in a subset of cells and not due to the barcodes themselves.

While no attempts at improving trans-splicing efficiency were successful, we were able to
substantially improve our protocol through the elimination of cis-spliced reads from the
amplification pool. These reads result from splicing of the IRIS 3’SS within transcript created
upstream from the promotor driving IRIS and compete for sequencing reads with real transspliced product. This observation, along with the fact that we saw cis-splicing taking place in
barcodes with successful trans-splicing into endogenous pre-mRNA, led us to conclude that basal
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transcript was being created after lentiviral integration. Our strategy involved adding restriction
enzymes, after several rounds of cDNA amplification, to cleave the cDNA between priming sites,
thus removing it from the amplification pool. One hypothesis was that IRIS integrating near or
within genes was being driven by endogenous promotors. However, this hypothesis was rejected
as adding restriction enzymes that digested sites at the 5’ end of the proposed full-length
transcript did not eliminate all cis-splicing. Thus, we concluded that basal transcription was
starting at various points along the integration product. By analyzing the location of cis-splicing
events, we were able to determine several hotspots to target for removing cis-spliced material.
Here we saw great success with our U1snRNA fused IRIS as this construct had the most
concentrated cis-spliced hotspots allowing us to target them all with one restriction enzyme.
Using this strategy, we saw a major improvement in ability to recover trans-spliced reads, going
from only 10% of IRIS reads consisting of trans-spliced material in our original construct and
protocol, to an 84% recovery rate. This also largely solved the problem we saw in our uneven
distribution of genes and unique splicing events per barcode with a shift in the distribution of
genes recovered per barcode, going from 48% of barcodes having zero trans-splicing events, to
only 10% of barcodes without trans-splicing.

Despite our success in reducing noise in our protocol, IRIS remains unstable for scRNA-seq
experiments in its current state as too few barcodes contain enough unique trans-splicing events
to perform transcriptomic analysis. It is possible, and likely, that deeper sequencing may lead to
more trans-splicing events per barcode, however this would not be a cost-effective use of
resources for most laboratories given the other more mature scRNA-seq barcoding strategies
available. An additional barrier to making IRIS usable is that we do get as many sequenceable
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reads back form an IRIS experiment as we should. Only about 10-20% of the reads we expect
from a run are typically received. For example, sequencing runs that should give us 1,000,000
reads frequently result in 100,000 to 200,000 reads. TA cloning and sanger sequencing of the
library suggests that non-sequenceable material is amplified during the tag-mentation
amplification step. Success has been seen in limiting amplification cycles and pooling
tagmentation products, however additional experimentation and optimization would be
necessary before committing to a full run. Another factor to consider is that additional
sequencing would not guarantee sufficient trans-spliced reads were available to be sequenced. It
is possible that at the current trans-splicing efficiency, there would not be enough events in
enough cells to perform transcriptomic analysis, even if 100% of trans-splicing events were
captured. However, this remains speculation, as a full next generation deep sequencing run has
not been performed using our most up-to-date protocols and constructs.

2.3.2 Future directions
While thus far IRIS has not proven sufficient for generating scRNA-seq data, the technology may
still have a bright future as a method for understanding the impact of ESRs on splicing and for
screening pre-mRNA trans-splicing molecules (PTMs). While splicing donor barcodes did not
show any enrichment for ESEs, our analysis shows that IRIS in its current state is able to enrich
for known ESSs that inhibit splicing. IRIS could be used in its current state to discover novel ESSs
by eliminating the restriction digestion which eliminates un-spliced transcript from the protocol
and examining which barcodes have fewer than expected trans-splicing events. This enrichment
scheme could be taken further by expressing an out of frame counter selection marker along
with IRIS, such that it was only in frame and active upon splicing. This would allow us to counter
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select against successful trans-splicing events and enrich for ESSs. Barcodes taken from our
current data sets that are known to trans-splice could be used as positive controls. Our
expectation would be that these motifs when cloned into a single barcode IRIS construct would
not trans-splice efficiently compared to the control. These ESS enriched barcodes could then be
clustered or used for motif analysis to discover novel ESSs which could then be searched for in
the genome. We would expect these novel ESSs to appear near computationally predicted splice
sites. An interesting observation would be to find new ESSs enriched around sites which were
predicted to be splice sites but are not known to splice (i.e., containing the correct dinucleotides,
a branch point and polypyrimidine tract). We could then mutate these ESSs and observe whether
these splice sites become active.

One of the most exciting alternative applications of IRIS could be as a screen for pre-mRNA transsplicing molecules (RTMs). Spliceosome-mediated RNA trans-splicing or SMaRT has shown great
promise as a therapeutic strategy for correcting deleterious mutations at the RNA level. Binding
domains are regions of RTMs that base pair with regions of the target transcript to localize transsplicing. Current screening methods for RTM binding domains are preformed via mini genes on
plasmids. These screens are low-throughput, labor intensive and do not always recapitulate
behavior in-vivo. Sequence homologies in these regions or the presence of splice sites can result
in un-wanted non-specific trans-splicing events which are difficult to predict until the molecules
are validated individually. Further, while trans-splicing efficiencies have reached up to 99% in
reporter-based assays, much lower levels are typical in endogenous settings. (Wally et al., 2012).
Finally, large regions of intronic and exonic transcript must be searched to find effective binding
domains and, despite many successful RTMs being developed, few conclusions have been able to
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be drawn as to what makes for a successful binding domain design. IRIS could be adapted to
solve these problems using few modifications to the technology in its current state. The IRIS
construct, sequencing and computational pipeline allow for the selective amplification and
analysis of trans-splicing events on a single cell level. This single cell resolution, and the ability to
use next generation sequencing to link barcodes to specific trans-splicing events, is what would
make IRIS the perfect tool for high-throughput mass screening of binding domains for RTMs.
Oligo libraries with binding domains spanning the entire length of exons and introns could be
ordered as oligo pools and attached to the IRIS 3’SS and barcodes unique to each binding
domain. These could then be used to generate an IRIS library where each barcode represents a
specific binding domain sequence and cloned into lentivirus. A modified IRIS protocol could then
be followed using a forward primer in the targeted exon in place of the usual template switched
first strand synthesis primer.

As a proof of concept, we have run this protocol using the positive control TD-tomato IRIS fusion
and shown that the IRIS reads recovered mapped back to the TD-tomato mock fusion. With this
modification, our standard IRIS protocol can be used to selectively amplify and report transsplicing events from a single gene. In parallel with our standard IRIS experiment, a portion of the
RNA would be used to amplify and quantify unspliced product using a forward primer specific to
IRIS that has not trans-spliced. The two libraries would then be run with different sequencing
indexes and the ratio of trans-splicing events to unspliced product for each barcode would be
compared. These barcodes could then be used to identify which RTMs were best at trans-splicing
into target endogenous RNA. A third pool of the RNA could be run through the standard IRIS
protocol in parallel to access each RTMs off target trans-splicing. The benefits of such a protocol
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would be numerous over current methods. First, any number of RTMs could be assessed in
parallel for trans-splicing efficiency. Efficiencies of successful RTMs have been shown to transsplice up to 40% of endogenous RNA and the use of a forward primer would add greater
specificity to the protocol. Thus, many of the amplification and noise problems we have seen in
the non-targeted IRIS protocol would no longer be problematic. Second, as this method screens
for endogenous trans-splicing events, this would eliminate the disparities seen between
reporter-based assays and in-vivo applications. Finally, as the standard IRIS protocol is already
well suited to capture non-targeted splicing events, we could simultaneously screen for effective
RTMs while also assessing off target effects.

2.4 Materials and Methods
2.4.1 Plasmids and cloning
All IRIS plasmids were cloned from the pSMAL-empty-GFP lentiviral construct (pRM1212). The
IRIS sequence consists of the following parts in order. A spacer sequence: AATTCTGCAGATA
TCCAGCACAGTGGCGGCC, the IRIS 3’ splice site: TACTTATCCTGTCCCTTTTTTTTCCACAG, the prebarcode spacer: CTAGAG, and a 16N barcode. An example of a full IRIS sequence is as follows:
AATTCTGCAGATATCCAGCACAGTGGCGGCCTACTTATCCTGTCCCTTTTTTTTCCACAGCTAGAGNNNNN
NNNNNNNNNNN. The CMV-IRIS (pRM1942) construct consists of IRIS driven by a CMV promoter.
This was done by cutting pSMAL with PacI and Xbal and inserting CMV followed by IRIS into the
vector via Gibson assembly. TD-IRIS (pRM1943) was cloned by amplifying TD-tomato and
inserting this construct behind the CMV promotor of CMV-IRIS followed by a pre-spliced IRIS
construct starting at the IRIS pre-barcode sequence (PBS). U15Pr (pRM1944) IRIS was cloned by
ordering a fragment from Genewiz consisting of the IRIS sequence inserted into the sequence for
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U1snRNA behind a U1 promoter. CMV-IRIS libraries were cloned by ordering IRIS sequence
ultramers with randomized 16N barcodes (IDT) and cloned via Gibson assembly by cutting at the
BstXI in IRIS CMV, using homology arms extending into the SMART sequencing primer just
upstream of WPRE. The scrambled version of IRIS was created via the same process with the 3’SS
of IRIS replaced by the following sequence: TTGTCACTCCATTATCTATCTCTGTCCTT. U15Pr libraries
were cloned by ordering IRIS sequence ultramers with randomized 16N barcodes (IDT) and
cloned via Gibson assembly by cutting at BmtI and Sal1 and inserting via homology at those
locations.

2.4.2 Lentiviral library preparation
Lentivirus for each library was created in HEK293t cells in T150 flasks using the standard Mitra
lab lentivirus protocol for complex libraries and titers were assayed via GFP transduction in
HEK293t. Libraries were generated using Gibson assembly into the vectors described above. To
generate complex barcoded libraries, 245 x 245 x 25mm plates (Fisher Scientific) were coated in
LB-agar with ampicillin. Gibson assemblies were diluted 1:3 in sterile H20 and transformed into
high-efficiency E. cloni 10G ELITE electrocompetent cells (Lucigen) via standard protocols. After 1
hour of growth in recovery medium cells were plated onto the 245 x 245 x 25mm LB-amp agar
plates such that each plate contained approximately 100,000 colonies. This required
approximately 25-30 plates per library. Plates were grown overnight at 37 C until individual
colonies could be seen. To harvest each plate 10 mL of liquid LB-Amp was added and the plate
scraped using a metal cell scraper which was flamed and kept in ethanol between uses. This
liquid was transferred to 50 mL conical tube and an additional 10 mL of liquid LB-Amp was added
to the plate for a second scraping and harvesting. All harvested samples were then combined
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and spun down, and pellets were processed via maxi-prep (Qiagen) resulting in the packaging
plasmid library used to create lentivirus.

2.4.3 Cell culture and lentiviral transduction
HEK293t cells were cultured in Dulbecco's Modified Eagle Medium (Gibco) with 10% FBS at 37
degrees Celsius at 5% CO2 and maintained in flat bottom T75 flasks. Cells were split every two
days or whenever they reached 80% confluence. In transduction experiments 100,000 cells were
placed in falcon tubes in 2 mL of media along with the appropriate volume of virus to achieve an
MOI of 0.3 and centrifuged at 800 x g for 30 minutes at room temperature. Multiple falcon tubes
were used for larger experiments. Cells were then resuspended and plated in 6 well plates.
When cells reached 80% confluence, all cells were trypsinized and transferred into T25 flasks.
This was done to prevent sub-selection and expansion of individual barcodes. When cells
reached 80% confluence in T25 flasks, all cells were again transferred to T75 flasks. After 5 days,
cells were harvested for flow cytometry and GFP positive cells were sorted into Eppendorf tubes
in 300 ul of RNAprotect (Qiagen) in aliquots 10,000 cells per tube.

2.4.4 IRIS protocol
The following primers are used in the IRIS protocol:
Primer
PJM48
PJM51
PJM52
PJM65
PJM71
PJM72
PJM75

Sequence
AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGT*A*C
AAGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
AAGCAGTGGTATCAACGCAGAGTAC
rUrGrArArArGrCrCrArUrArCrGrGrGrArArGrCrArArUrArGrCrA
CTGAAATGCCCTAGGCTAAGCTTGTrGrGrG
CTGAAATGCCCTAGGCTAAGCTTGT
GCAGCGTATCCACATAGCGT
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PJM105
PJM106
PJM125
PJM126
PJM127

AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGCACAAATTTTGTAATCCAGAGGTTGAT*T*G
AAGCAGTGGTATCAACGCAGAGTACTACG
CCGAACCGGGUGGCGAAA
AACCGGCAGCCAATGCCA
AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTATCAACGCAG*A*G

(1) Total RNA was extracted using a Direct-zol RNA MicroPrep kit and quantified. 4.75 ul of
purified RNA from each extraction was placed in a PCR tube. (2) 1 uL of 10 uM of WPRE1-RNA
(PJM65) (PJM51 for Controls) (PJM125 for U15P) primer was added and heated to 72 C for 2
minutes, then incubated at 4 C for 1 minute. (3) For each tube the following was added: 2 ul of
20% Ficoll PM-400, 2 uL Maxima RT buffer, 1ul 10 mM dNTPs, 0.5 ul 50 uM TSO (PJM71) and 0.5
ul Maxima H- RT. The tubes were then incubated at 42 C for 90 minutes, then heat inactivated
for 5 minutes 85 C. (4) An RNase cocktail (0.5 ul RNase I, and 0.5 ul RNase H) was added to
remove terminal riboGs from the TSO and destroy the WRE1-RNA FSS primer; The solution was
incubated for 30 minutes at 37 C. (5) For each sample tube, 13.2 uL H2O, 0.4 uL of 100 uM
PJM72, 0.4 uL of 100 uM PJM75 (PJM52 for Controls) (PJM126 for U15P), and 25 uL of 2x Kapa
Hifi super mix were added. Samples were then run using the following cycles to create cDNA 95
C for 3 min, 3 cycles of [98 C for 20 sec, 67 C for 20 sec, 72 C for 3 min], then a final cycle of 72 C
for 5 min. (6) 1 ul of EcoRV (BmtI for U15P) was added to each tube to remove unspliced IRIS
and incubated at 37 C for 1 hour, then heat inactivated at 80 C for 20 min. In experiments where
cis-splicing digestion was performed an additional 1 ul of the appropriate enzyme was added as
well (Spf1 for IRIS-CMV and BsmBI for U15P experiments). The following PCR cycle was then
performed to finish amplification of cDNA: 95 C for 3 min, 13 cycles of [98 C for 20 sec, 67 C for
20 sec, 72 C for 3 min], then a final cycle of 72 C for 5 min. (7) An AMPure bead cleanup at 0.8x
was then used to remove primers and enzyme from the tubes and cDNA was quantified on a
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Qubit using high sensitivity DNA reagents. (8) Tagmentation was performed on 1 ng of cDNA
raised to total volume of 5 uL using dH2O. In each tube, 10 ul of Nextera TD and 5 uL of ATM
enzyme were added and the tubes were incubated at 55 C for 5 minutes. 5 uL neutralization
buffer was then added to each tube and incubated at RT for 5 minutes to stop tagmentation. (9)
15 ul Nextera PCR mix (NPM), 8 uL dH2O, 1 uL of 10 uM PJM105 (PJM48 for Controls) (PJM127
for U15P), and 1 uL of Nextera 70X oligo was added to each tube. The following cycle was then
performed to amplify the tagmented sequencing library: 95 C for 2 min, 16 cycles of [95 C for 30
sec, 61 C for 30 sec, 72 C for 3 min], then a final cycle of 71 C for 10 min. (10) An AMPure bead
cleanup was performed again at 0.8x to remove primers and enzyme from the tubes and the
final cDNA was quantified on a Qubit using high sensitivity DNA reagents as well as a Tapestation
(Agilent) using D1000 high sensitivity tapes. Libraries were then diluted to 10nM in 20ul of H20
and submitted for Illumina sequencing using PJM106 as a sequencing primer. Note: IRIS libraries
frequently needed to be loaded at higher-than-expected concentrations to achieve sufficient
reads.

2.4.5 Computational pipeline
Upon receiving reads a custom computational pipeline was run on read 1 of the fastq files for
each experiment (Figure 2.12). The read 1 file was re-named iris.fastq for the purposes of the
pipeline. Reads are structured such that the first 16 base pairs make up the IRIS barcode,
followed by the six base pair IRIS pre-binding sequence used to identify IRIS reads “CTCTAG” and
then spliced endogenous mRNA. Hg38 was used to map RNA reads back to the human genome.
To account for cis-spliced plasmids and unspliced reads, upstream plasmid DNA up to unspliced
IRIS, the unspliced sequence of IRIS itself, and downstream plasmid DNA were concatenated to
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hg38 as independent sequences in FASTA format. The computational pipeline was followed: (1)
Fastp (Chen et al., 2018) was used to clean the data of PolyG’s from the sequencer and remove
low quality reads. (2) IRIS Tools.py (custom script) was used to filter out non-IRIS reads and
create a csv file of all read-barcode pairs. (3) Casscade.py (custom script) was used to collapse
barcodes via hamming distance. The program works by sorting barcodes by read count and
proceeding down the list collapsing all barcodes below the current one on the list. This program
also removes low quality barcodes with few reads. Finally, the program makes a whitelist of
collapsed barcodes. (4) UMI-Tools (T. S. Smith et al., 2017) uses the whitelist file generated by
Casscade.py to write whitelist corrected barcodes for each read into the readID of the FASTA file
for later processing. (5) Bowtie2 (Langmead & Salzberg, 2012, p. 2) aligns IRIS reads in processed
FASTA file to the modified hg38 human genome (described above). Samtools (Danecek et al.,
2021) is used to convert the alignment file, iris.sam, into a .bam file and Bedtools (Quinlan &
Hall, 2010) is used to convert the iris.bam file into a bed file, iris.bed. (6) Homer is used to
annotate the bed file with gene information and produces an iris_annotated.txt file which can be
useful for per barcode analysis of reads and genes. (7) IRIS_DGE.py (custom script) converts the
annotated IRIS file into a digital gene expression matrix usable in common single cell sequencing
packages such as scAmpi (Bertolini et al., 2021) or Seurat (Hao et al., 2021). (8) Finally, IRIS Stats,
countGenesCis3.py, converts the iris_annotated.txt file into a human readable CSV file,
gene_summary_cis_exp.csv, that can be used to analyze barcode level statistics of the IRIS run.
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Figure 2.1

Figure 2.1 Overview of Internal RNA Identifier Sequencing. (1) A schematic of the IRIS construct
including the IRIS 3’ splice site, pre-barcode spacer (PBS) and priming sites. 16N randomized
barcodes are cloned into the IRIS lentiviral packaging construct and lentivirus is produced. (2) Cells
and tissue are transduced at a MOI of 0.3 - 0.5. (3) Bulk RNA is extracted from the sample. (4) First
strand synthesis specific to trans-spliced IRIS RNA is performed and cDNA is created. (5)
Tagmentation is performed on the cDNA library to allow for sequencing of trans-spliced IRIS ends.
(6) Trans-spliced reads are mapped back to genes in the organism’s genome and barcodes are
used to assign reads to individual cells.
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Figure 2.2

Figure 2.2 Quantification and analysis of a single barcode IRIS experiment. (A) (1) Single barcoded
IRIS acceptor RNA including a 3’ splice site, pre-barcode spacer (PBS) and priming site. EcoRV can
be used to cut unspliced IRIS. (2) Fusion of endogenous RNA and IRIS after trans-splicing. (B)
Breakdown of total reads from a single IRIS experiment in HEK293T cells. 41% of reads contained
the IRIS PBS identifying them as IRIS reads. (C) Breakdown of reads with the IRIS PBS. 25% of
reads contained unspliced construct, 59% cis-spliced RNA and 16% trans-spliced endogenous
RNA.
86

Figure 2.3

Figure 2.3 Analysis of dinucleotides at IRIS trans-splicing junctions. (A) Canonical splicing takes
place at GU or AU dinucleotides at the 5’ end of the spliced-out intron, and AG dinucleotides at
the 3’ intron end. (B) Breakdown of downstream dinucleotides in genes trans-spliced by IRIS. 63%
of IRIS splice junction locations spliced at GU dinucleotides while 23% spliced at AU dinucleotide
junctions.
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Figure 2.4

Figure 2.4 Mock IRIS trans-splicing mixing experiment. (A) TD-tomato transcript fused with the IRIS
PBS and barcode serve as positive control for successful splicing events. (B) IRIS with a scrambled
3’SS serves as a control for IRIS that does not splice. (C) HEK293T Cells transduced with TD -tomato
fused IRIS and scrambled IRIS were mixed at different ratios to simulate varying degrees of transsplicing efficiency.
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Figure 2.5

Figure 2.5 Quantification and analysis of barcoded IRIS library. (A) HEK293t cells were transduced
with a 2.5 million barcode IRIS library and 10,000 IRIS expressing cells were sequenced. 70% of
total reads were identified as IRIS reads. (B) Breakdown of IRIS reads. 6% of reads contained
unspliced construct, 84% cis-spliced RNA and 10% trans-spliced endogenous RNA. (C) Histogram
of cell barcodes containing IRIS reads binned by number of unique genes.
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Figure 2.6

Figure 2.6 IRIS fusion with U1 small nuclear RNA (U1snRNA). (A) Design of the IRIS U1snRNA fusion
construct (U15P-IRIS). A barcoded IRIS construct is incorporated into the 5’ end of the U1snRNA.
Regions where U1snRNA binds to incorporate into the U1snRNP complex and binds to splice
junctions are left intact. (B) Analysis of reads from a single barcode U15P-IRIS experiment. 29% of
total reads were identified as IRIS reads. (C) Breakdown of IRIS reads. 13% of reads contained
unspliced construct, 61% cis-spliced RNA, and 26% trans-spliced endogenous RNA.
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Figure 2.7

Figure 2.7 Cis-splicing locations mapped to transcript from the lentiviral integration product in a
CMV-IRIS experiment. (A) Location of cis-spliced reads in a barcoded CMV-IRIS IRIS experiment
using the standard protocol. (B) Addition of Spf1 restriction enzyme eliminates cis-splicing near
the restriction site and at various points along the transcript, but cis-splicing hotspots near the
cPPT, GFP and CMV promotor driving IRIS remain.
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Figure 2.8

Figure 2.8 Cis-splicing locations mapped to transcript from the lentiviral integration product in a
U15P-IRIS experiment. (A) Location of cis-spliced reads in a U15P-IRIS experiment using the
standard protocol. (B) Addition of BsmBI restriction enzyme eliminates nearly all major cis-splicing
sites within the construct leaving only residual events near the restriction site itself.
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Figure 2.9

Figure 2.9 Models of cis-splicing in transcript created from genome integrated IRIS. (A) If IRIS
lands within a gene, promoters from outside of the lentiviral integration region driving the gene
may create long IRIS transcripts capable of cis-splicing. (B) Integration into open chromatin, or
otherwise active regions of the genome, leads to basal transcription within the IRIS lentiviral
integration creating transcripts of varying lengths capable of cis-splicing.
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Figure 2.10

Figure 2.10 Quantification and analysis of a barcoded U15P-IRIS library. (A) HEK293t cells were
transduced with a U15P-IRIS IRIS library consisting of over 1 million barcodes and 10,000 IRIS
expressing cells were sequenced. 62% of total reads were identified as IRIS reads. (B) Breakdown
of IRIS reads. 1% of reads contained unspliced construct, 13% cis-spliced RNA and 86% transspliced endogenous RNA. (C) Histogram of cell barcodes containing IRIS reads binned by number
of unique genes.
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Figure 2.11

Figure 2.11 Enrichment of ESEs and ESSs in barcodes with IRIS splicing events vs unspliced
barcodes. IRIS barcodes with or without cis and trans-splicing events were split into two categories
and scanned for a list of 558 ESE and 172 ESS published motifs computationally predicted by a
Neighborhood Inference algorithm. (A) Spliced barcodes showed no significant enrichment in
average ESE content over unspliced barcodes. (B) Unspliced barcodes showed a 47% enrichment
in average ESSs over spliced barcodes (P <= 0.001). A Mann–Whitney U test was used to preform
statistical analysis between the two populations.

95

Figure 2.12

Figure 2.12 Computational pipeline for IRIS. Read 1 from an IRIS experiment is used in this pipeline
to create a gene_summary.txt file, digital gene expression file, and annotated.txt file. The
gene_summary.txt file can be used to view barcode level statistics including unique trans-splicing
events, trans-spliced reads, unspliced reads, unique genes per barcode and the location of cissplicing events. The digital gene expression file can be used in any standard single cell analysis
package. The annotated.txt file can be used to for read level analysis for each barcode and includes
which reads were mapped back to which barcodes as well as what genes they were mapped to in
the genome.
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Chapter 3:
Single-stranded RNA oligonucleotides that recruit endogenous
hnRNPA1 enable the targeted reduction of gene expression
3.1 Abstract
Targeted gene knockdown has become one of the most powerful tools in molecular biology and
holds substantial promise in therapeutic applications. While existing technologies such as siRNAs,
CRISPRi, and ASOs effectively and specifically reduce gene expression, few can be used to first
discover the genes that influence a particular phenotype and then directly transition to being
used as oligonucleotide therapeutics. Thus, a tool that could help bridge the gap between target
discovery and the development of therapeutic leads would benefit the scientific community.
Here, we present hnRNPA1 recruiting oligonucleotides, or AROs, as single-stranded RNA (ssRNA)
molecules that knockdown transcript levels of target genes. AROs target specific pre-mRNA
transcripts via sequence homology and leverage the ubiquitous and abundant endogenous RNAbinding protein hnRNPA1 to degrade target transcripts. Using RT-qPCR, we show that AROs
effectively knock down target genes when delivered via a plasmid and expressed using a Pol II
promoter or when delivered directly as single-strand RNAs. Additionally, as proof of principle, we
use a ssRNA ARO to knockdown KRT14 in squamous cell carcinoma and show reduced invasive
potential. We believe AROs fill an important niche in the scientific toolbox by taking advantage of
endogenous RNA binding machinery for RNA knockdowns.
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3.2 Introduction
The ability to manipulate RNA expression and splicing is one of the most powerful tools in
research and holds great promise for therapeutic applications. In basic science, the ability to
target and knockdown a specific gene of interest using tools such as siRNA and CRISPRi has
allowed us to unravel the intricacies of biological pathways, leading to many new discoveries
(Cong et al., 2013; Gilbert et al., 2014; Kampmann, 2018; Mullenders et al., 2009). In medicine,
targeted manipulation of expression and splicing through antisense oligonucleotides (ASOs) has
led to several promising therapeutics. For instance, the FDA has approved ASO-based treatments
for both Duchenne muscular dystrophy, a child-onset disease in which patients progressively
lose muscle function resulting in wheelchair dependency, the need for ventilation assistance and
ultimately premature death (Aartsma-Rus & Krieg, 2017), and spinal muscular atrophy in infants,
a disease caused by mutations in SNM1 leading to musculoskeletal wasting and respiratory
failure (Stein & Castanotto, 2017).

While a variety of technologies exist to knockdown or modify pre-mRNA in the cell, few options
are available that bridge the gap between research and clinical settings. Tools such as siRNA,
lentivirus, and plasmid expression are frequently employed as screening tools to find therapeutic
targets (Koike-Yusa et al., 2014). However, the end products of these methods often run into
roadblocks as therapeutics themselves. siRNA therapies are challenged by double-stranded RNA
degradation by the immune system, off-target effects due to improper strand loading, and
toxicity due to oversaturation of the RNAi machinery (Nogrady, 2019). CRISPR-based
technologies require the introduction of the exogenous Cas9 protein, which poses a significant
barrier for many applications, and their off-target effects are still being evaluated for safety
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(Tycko et al., 2019). These limitations result in the identification and characterization of gene
targets with technologies that are either clinically unviable or suboptimal, thus requiring their reevaluation with small molecule screens or other therapeutic methods, resulting in significant
delays in translating bench observations to the clinical setting.

While ASOs have found purchase as therapeutics, they are heavily reliant on a variety of
nucleotide chemistries and backbone modifications to achieve the desired results (Roberts et al.,
2020). ASOs that degrade their targets are often composed of RNA with central DNA “gap”
sequences that hybridize with homologous regions of RNAs and trigger RNase H mediated
degradation, whereas sterically hindering ASOs, such as morpholinos, incorporate morpholine
moieties instead of ribose backbones and modified phosphonodiamidite linkages to evade
degradation (Ekker, 2006). Reliance on these chemistries and modifications makes it difficult to
perform large ASO based screens to identify genes that can be targeted with this modality. For
example, this methodology is incompatible with the production of lentiviral libraries, which
infect cells clonally and thereby can greatly parallelize the search for candidate molecules
through a combination of cell culture and next-generation sequencing.

A technology that could seamlessly transition between construct-based screening and the
synthesis of biologically functional molecules would greatly benefit both the research and clinical
communities. The ideal technology would require minimal chemical modifications to transition
from screening construct to lead compound, be compatible with modern molecular biology
techniques, such as plasmid or viral expression, and would not require exogenous proteins to
function. To address this need, we created hnRNPA1 recruiting oligonucleotides (AROs) to serve
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as both a standalone technology and paradigm for using endogenous RNA binding proteins to
manipulate pre-mRNA.

hnRNPA1 is a ubiquitously expressed RNA binding protein with multiple roles that are still being
uncovered; however, the protein is best known for the role it plays in alternative splicing and
RNA processing (Jean-Philippe et al., 2013). Splice sites are defined by short 5’ (GU) and 3’ (AG)
sequences flanking introns. While these dinucleotides are required for splicing, they do not
contain enough information to correctly specify splice junctions. As a result, regulatory proteins
such as SR proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) must bind to
exonic splice enhancers (ESEs) and exonic splice silencers (ESSs) respectively to properly define
exon-intron boundaries (Lee & Rio, 2015) . Binding of hnRNPA1 to an ESS on pre-mRNA blocks
the binding of SR proteins and splicing machinery leading to cooperative recruitment of
additional hnRNPA1 and suppression of the splice site (Jean-Philippe et al., 2013).
We sought to harness the ability of hnRNPA1 to suppress splice site selection by recruiting it to
targeted pre-mRNA molecules. To do so, we constructed single-strand RNA molecules herein
referred to as hnRNPA1 recruiting oligonucleotides or “AROs” (for A1 recruiting oligonucleotide).
AROs consist of two parts, a short (20 – 25 bp) RNA oligonucleotide targeting domain which is
complementary to the target pre-mRNA, and an hnRNPA1 recruiting loop derived from the HIV
ESS 3, which binds to the RNA binding domain RRM1 of hnRNPA1 and recruits the protein (Jain
et al., 2017) (Figure 3.1A). We hypothesized that, upon recruitment to the target pre-mRNA,
hnRNPA1 would displace local SR proteins and splicing machinery (Figure 3.1B) resulting in the
suppression of regional splice sites, leading to frameshifts caused by aberrant exon skipping or
intron inclusion.
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Due to the ubiquitous nature of endogenous hnRNPA1 across cell types, AROs do not require any
exogenous proteins to function. Further, as AROs do not rely on DNA-RNA hybrids to trigger
RNAase H degradation, AROs can be produced entirely as RNAs within the cell. Finally, their
single-stranded nature and simple mechanism of action allow them to be transcribed in vivo
using a standard Pol II promotor, so they are compatible with standard lentiviral screening
methodologies. In the following experiments, we demonstrate that AROs can suppress target
mRNA transcripts, are biologically functional, and can be expressed using standard molecular
biology constructs or delivered directly as single-strand RNA oligonucleotides.

3.3 Results
3.3.1 AROs knock down KRT14 expression in an hnRNPA1 specific manner
To test whether AROs can knock down gene expression in a targeted manner, we created a 23
base-pair antisense RNA molecule with homology to exon 7 of the KRT14 gene and fused an
hnRNPA1 recruiting loop to either the 5’ end, the 3’ end or both sides of the targeting
oligonucleotide. KRT14 was chosen as a knockdown target because it has been implicated as a
driver of the epithelial-mesenchymal transition in numerous cancers, (Bilandzic et al., 2019, p.
14; Papafotiou et al., 2016, p. 14) and Exon 7 was chosen due to its small size (47 base-pairs) and
because it contains several motifs for ASF/SF2 exonic splice enhancer binding, a regulatory
element that hnRNPA1 has been shown to repress (Cartegni et al., 2003; Kashima et al., 2007).
As controls, we also tested an oligonucleotide containing only the 23 bp targeting domain (i.e. an
“antisense only” control with no A1 recruiting loop) and an ARO with a scrambled targeting
domain (Fig 2A), which respectively served to determine whether the targeting oligonucleotide
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or hnRNPA1-recruiting loop alone influenced KRT14 expression. Human keratinocytes, HaCat
cells, were chosen as a model cell line for initial experiments due to their robust expression of
KRT14.

Because hnRNPA1 binds cooperatively (Jean-Philippe et al., 2013), we hypothesized that we
would see the greatest knockdown of gene expression with the ARO containing two flanking
hnRNPA1 recruiting loops (ARL-Oligo-ARL). Consistent with our expectations, we observed a 56%
knockdown of KRT14 gene expression in ARL-Oligo-ARL compared to the carrier control (P <=
0.001), and a 53% knockdown of expression compared with the targeting oligo only (Oligo)
control (P <= 0.01) indicating that the hnRNPA1 recruiting loop was required for knockdown to
occur (Figure 3.2B). We also saw significant knockdown of the ARL-Oligo (P <= 0.05) and OligoARL (P <= 0.05) experimental conditions (18% and 29% respectively), when compared to the
targeting oligo only (Oligo) control. Interestingly, we observed a small (15%) but statistically
significant difference between the targeting oligo only control (Oligo) and the scrambled
targeting oligo control attached to an hnRNPA1 recruiting loop (scrOligo-ARL) indicating that the
presence of the ARL alone may have a minor knockdown effect on KRT14. Alternatively, it is
possible that the scrambled targeting oligo has off-target effects influencing the expression of
other transcripts which affect the expression of KRT14.
To test whether the effects of the AROs were hnRNPA1 dependent, each condition was repeated
in the presence of two validated siRNAs designed to knockdown hnRNPA1 (Figure 3.2B).
Concurrent loss of hnRNPA1 with expression of ARL-Oligo, Oligo-ARL, and ARL-Oligo-ARL caused
significant and complete loss of previously seen knockdown effects on KRT14 transcript (P <=
0.05, P <= 0.01 and P <= 0.01 respectively). In contrast, differences between the control
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constructs, scrOligo-ARL and Oligo, and their hnRNPA1 siRNA knocked down counterparts were
not significant. Taken together, our results demonstrate that AROs targeting KRT14 knock down
mRNA expression in a targeted and hnRNPA1 dependent manner.

3.3.2 AROs targeted to TBK1 knock down RNA expression across multiple locations
on exon 14
To evaluate whether AROs could knock down the expression of other genes, we designed AROs
against the TBK1 gene (Figure 3.3A). We targeted exon 14 because it contained multiple ASF/SF2
sites according to ESE finder (Cartegni et al., 2003) and because its moderate size (122 bp)
allowed us to evaluate multiple AROs targeting the same exon, as diagrammed in Figure 3.3A. To
investigate whether AROs act in a location-specific manner, we designed 5 different AROs
targeting exon 14 of TBK1 in 20 base pair segments and tested them in HaCat cells. All 5 AROs
significantly knocked down TBK1 expression (P =< 0.01) when compared to the mock
transfection carrier control. The largest knockdown was seen in ARL-TBK1-O3-ARL (51%) and the
smallest in TBK1-O5-ARL (37%). These results indicate that all AROs targeting exon 14 of TKB1
were effective at gene knockdown.

As a negative control, we included the ALR-Oligo-ARL construct targeting the KRT14 gene from
the previous experiment. As expected, the KRT14-targeting ARO did not decrease TBK1
transcript levels. Instead, we observed a significant (P <= 0.01) increase in TBK1 gene expression
when KRT14 is knocked down. We hypothesize that the increase in TBK1 expression is a
downstream result of perturbation of KRT14 expression levels.
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Our experiments do not seem to indicate any preference for targeting oligo location along the
length of the exon as all of the oligonucleotides that targeted exon 14 of TBK1 showed similar
knockdown effects.

3.3.3 AROs can be delivered directly via lipofection as synthesized oligonucleotides
A major appeal of AROs as a potential therapeutic is their small size and single-stranded nature.
Smaller molecules are easier to deliver and single-stranded RNA is not targeted by cellular
mechanisms that actively seek out double-stranded RNA for degradation. To determine if AROs
could be delivered directly as single-stranded RNA oligonucleotides, we ordered synthesized
AROs targeting KRT14 and tested them in HaCat cells. Each molecule was designed to contain
phosphorothioate bonds between the first two and last two bases to inhibit exonuclease
degradation. The targeting domain was the same sequence used in the previous plasmid based
knockdown experiment (Figure 3.1). We tested a single 5’ ARL (ARL-Oligo) as well as ARLs fused
to each end of the targeting oligo (ARL-Oligo-ARL) and compared them to a previously validated
siRNA targeting KRT14 at varying concentrations (Figure 3.4A).

We observed significant knockdown effects at all concentrations of ARL-Oligo and anti-KRT14
siRNA conditions, with diminishing returns at above 100nM. Interestingly, we did not observe
significant knockdown with ARL-Oligo-ARL oligos, despite this configuration being the most
effective in plasmid experiments, until concentrations of 1 µM. One possibility for this may be
that the ARL-Oligo-ARL may have had difficulty making it to the nucleus due to its increased size.
Another possibility is that interactions between complementary regions in the two ARLs on the
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oligo caused the targeting domain to be less available or degraded more quickly than its single
ARL counterpart.

3.3.4 Knocking down KRT14 via AROs in squamous cell carcinoma reduces cancer
migration capability
Having demonstrated that we can knock down genes via delivery of oligonucleotide AROs, we
next sought to test if ARO-mediated gene knockdown could achieve a therapeutic/biologically
functional effect. KRT14 expression has been shown to be important for metastasis and invasion
in several cancers including bladder and ovarian cancers (Bilandzic et al., 2019, p. 14; Papafotiou
et al., 2016, p. 14). SCC9 is a squamous cell carcinoma line used as a model for epithelialmesenchymal transition studies in head and neck cancer (Zhu et al., 2012). We hypothesized
that knocking down KRT14 in SCC9 using our ssRNA anti-KRT14 ARO would reduce the ability of
these cells to invade surrounding tissues.

To test this hypothesis, we lipofected SCC9 cells with a KRT14 targeting ARO (ARL-Oligo) or, as a
positive control, an siRNA against KRT-14, at 100 nM and assayed RNA expression by RT-qPCR.
After 48 hours a near complete knockdown of KRT14 transcript levels was observed in both
conditions (P <= .001) (Figure 3.4B). We also sought to verify knockdown of Cytokeratin-14, the
protein encoded by KRT14. We performed a western blot (Figure 3.5C) and observed a 38%
reduction of protein in the siRNA treated cells (P<=0.01) and a 24% knockdown in cells treated
with ssRNA anti-KRT14 ARO (P<=0.05). While this knockdown was less than the observed RNA
reduction, this is likely due to two factors: the long doubling time of SCC9 (~72 hours)
contributing to slow dilution of the protein, and the protein turning over at a slower rate than
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the RNA, which is actively being degraded in both conditions. Additionally, we observed that
differences in protein knockdown between the ARO and siRNA were not significant.
We next sought to assay the invasive potential of SCC9 cells after the loss of KRT14. 48 hours
after lipofection with synthesized oligonucleotides or siRNAs, cells were seeded into a Boyden
chamber to test their ability to invade into surrounding tissues. This assay uses a transwell that is
sealed on one side with a porous membrane coated with Matrigel. The transwell is then
suspended inside a larger well, and only invasive cells are able to migrate through the Matrigel.
48 hours after transfection, cells were seeded and incubated for 24 hours. Cells that invaded the
Matrigel were then stained, observed via light microscopy (Figure 3.5B), and counted. We
observed a significant decrease in invasive potential of cells treated with both the anti-KRT14
siRNA control (P<=0.05) as well as our ARO (P<=0.05) compared to cells treated only with
lipofectamine carrier. Cells treated with the KRT14 siRNA had 39% fewer cells migrate into
matrigel than the carrier control, while cells treated with the anti-KRT14 ARO had 43% fewer
cells relative to the carrier (Figure 3.5A).
The above results support two important conclusions. First that the knockdown of KRT14
negatively affects the ability of squamous cell carcinoma to invade surrounding tissues. Second
that AROs delivered as ssRNAs are biologically functional and able to knock down protein levels
in addition to RNA. We believe these experiments show the usefulness of AROs as novel and
useful biological tools for both RNA and protein perturbation.

3.4 Discussion and future directions
In this article, we present hnRNPA1 recruiting oligonucleotides (AROs), a new tool for mRNA
knockdown consisting of a short targeting oligonucleotide and a hnRNPA1 recruiting loop.
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Through a series of RT-qPCR experiments targeting KRT14 and TBK1, we have shown that AROs
expressed from plasmids are able to knock down the expression of two independent genes in a
targeted fashion. We have shown that both the antisense targeting RNA and the hnRNPA1
recruiting loop must be present for an efficient knockdown. We have also shown that AROs
function in an hnRNPA1 dependent manner. Finally, we have shown that AROs are functional in
multiple cell lines including human keratinocytes (HaCat) and squamous cell carcinoma cells
(SCC9) and can affect a loss-of-expression functional phenotype.

Our results suggest that the location of the sequence targeted by an ARO on the exon of interest
does not have a large influence on knockdown efficiency. We initially hypothesized that the
targeting location would have a bigger impact on ARO function. Specifically, we expected that it
would be necessary to direct AROs to splice junctions or to ASF/SF2 motifs, as preventing binding
of SR splice enhancer proteins is a known mechanism of hnRNPA1 splice site repression (JeanPhilippe et al., 2013; Kashima et al., 2007). One possible explanation is the cooperative
recruitment of hnRNPA1 molecules along RNA in the 3’ to 5’ direction (Jean-Philippe et al.,
2013). This might mean that an ARO binding at a downstream exonic sequence is sufficient to
suppress SR protein recruitment at upstream regions. Another possibility is that the exon we
choose was too small to see location specific effects. Larger exons with more space between
splice sites should be tested in the future to help answer this question.

A major advantage of AROs over most knockdown technologies is the ease with which they can
transition from promotor-based expression (i.e. from a plasmid or lentivirus construct) to RNA
oligonucleotides that can be directly delivered to cells or organisms. Here we have shown the
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utility of AROs as a potential therapeutic by synthesizing single-stranded RNA AROs and showing
that they are able to achieve similar levels of knockdown as their plasmid counterparts. By using
ssRNA AROs to knock down KRT14 in SCC9, a squamous cell carcinoma line used as a model for
epithelial-mesenchymal transition studies in head and neck cancer, we demonstrate that ARObased knockdown resulted in a biologically relevant phenotype – the decreased ability of
carcinoma cells to migrate in a cell invasion assay.

An unexpected finding in our RNA oligonucleotide experiments was that while the double ARL
ssRNA (ARL-Oligo-ARL) worked to some degree at high concentrations, the single ARL (ARL-Oligo)
achieved significantly better gene knockdown at lower concentrations. This contrasted with our
plasmid experiments which found that double ARL AROs performed best. A possible explanation
for this may be that the additional size or complexity of double ARL oligonucleotides may have
lessened their ability to make it to the nucleus. Another possibility is that complementary regions
between the two ARLs caused secondary structure leading to double-stranded portions of the
construct being degraded in the cytoplasm. This would be less likely to occur in the plasmid
construct as those AROs would be produced in the nucleus and would presumably have more
opportunity to affect pre-mRNA before being exported and degraded.

We hypothesize that AROs knock down gene expression by causing errors in pre-mRNA splicing
followed by nonsense-mediated decay. However, it is important to point out that there are
several plausible alternative hypotheses. For example, hnRNPA1 has been shown to bind to the
3’ UTR of some genes, and this can lead to mRNA deadenylation and degradation (Geissler et al.,
2016). This may be why binding along any point of an exon in pre-RNA seems to be effective.
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While more work will need to be done to determine the specific mechanism of action of AROs to
better understand and improve their function, their utility as biological tools in their current
form remains substantial.

AROs represent a novel paradigm for recruiting RNA binding proteins to pre-mRNAs via synthetic
constructs. Here we have shown that hnRNPA1 can be recruited via a short targeting
oligonucleotide to knock down transcript levels of a target gene. While more work will need to
be done to understand the exact mechanism of how AROs function, the work here illustrates
their potential as a novel, biologically functional way to knock down target transcripts through
the redirection of endogenous cellular machinery. Because RNA binding proteins are ubiquitous
and abundant across cell types, their recruitment to targeted pre-mRNAs may be a useful way to
modulate RNA production, modification, or degradation. The diverse array of functions they
perform and their directable nature make them an ideal source to mine for molecular biology
tools. The ability to express AROs, and similarly designed molecules, from a Pol II promoter also
has substantial advantages. AROs could be placed under the control of cell or tissue specific
promotors and used in tissue specific studies or placed behind activatable promotors.
AROs can both be expressed by constructs or used directly as ssRNA molecules with little
modification. This dual functionality puts them in a unique position to bridge the gap from highthroughput screens to independently functional molecules. We believe AROs fill an important
niche in the scientific toolbox and we hope the work here can serve as a template for future
constructs that make use of the potential of RNA binding proteins as tools for the modulation of
RNA homeostasis.
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3.5 Materials and methods
3.5.1 Cell culture
HaCat cells were cultured in Dulbecco's Modified Eagle Medium (Gibco) with 10% FBS at 37
degrees Celsius at 5% CO2 and maintained in flat bottom T75 flasks. SCC9 cells were cultured in a
3:1 mixture of Ham’s F12 Medium (Gibco) and Dulbecco's Modified Eagle Medium
supplemented with 10% FBS and maintained at 37 degrees Celsius at 5% CO2 in T75 flasks. For
ARO RT-qPCR experiments, cells were grown in 24 well plates and lipofected with 500 ng of
plasmid using lipofectamine 3000 (Thermofisher). In knockdown experiments, two independent
siRNAs (Life Technologies, Silencer Select Pre-Designed siRNA) were co-transfected at a final
concentration of 10 nM during lipofection, and knockdown of the target gene was verified via
RT-qPCR. In experiments involving direct delivery of single-stranded RNA, cells were grown in 24
well plates and lipofected using lipofectamine 3000 (Thermofisher) at the concentrations listed.
For Western blot and Boyden chamber experiments, cells were maintained in 6 well plates prior
to seeding.

3.5.2 Boyden chamber invasion assays
20,000 SCC9 cells were suspended in 200 ul of serum-free growth media and seeded inside a
matrigel-coated transwell. 750 ul of growth media containing 10% FBS was added to the larger
well. Cells were allowed to migrate through the pores to the other side of the membrane by
incubating them at 37 degrees Celsius for 24 hours. After 24 hours of incubation, the transwells
were washed in PBS, fixed in 100% Methanol for 2 minutes, and then stained in crystal violet
solution for 20 minutes. Excess crystal violet was washed off by dipping the transwells in water.
The transwells were then left to dry following which they were imaged in a brightfield
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microscope. A custom Image J script was used to count cells that migrated into the Matrigel
coated side of the transwell.

3.5.3 Western Blots
Cells were harvested 48 hours after lipofection using RIPA buffer and total cellular protein was
extracted. A BCA assay (Pierce BCA Protein Assay Kit) was used to determine the protein
concentration of each sample. 5 ug of lysate from each sample was loaded into a Mini-PROTEAN
TGX stain-free precast gel (Bio-Rad) and resolved. Once proteins were resolved, gels were
activated on a ChemiDoc (Bio-Rad) imager and were then transferred to a polyvinylidene
difluoride (PVDF) membrane. Membranes were probed with mouse Cytokeratin 14 antibody
primary antibody (Life Technologies) and HRP conjugated goat anti-mouse secondary antibody
(Santa Cruz Biotechnology). Total proteins and chemiluminescence was imaged on the ChemiDoc
and Image Lab Software (Bio-Rad) was used to analyze protein abundance.

3.5.4 Statistical analysis
A Student’s t-test was used to test for significance between groups. Experiments were
performed in at least two technical replicates unless otherwise stated and error bars show plus
and minus standard deviation. P values of <= 0.05 were determined to be significant.

3.5.5 RT-qPCR
Cells were grown for 48 hours after lipofection before being harvested using RNAprotect
(Qiagen). Total RNA was extracted using Direct-zol RNA microprep kit and quantified. Each
condition was performed in triplicate using 50 ng of total RNA. For each 20 ul reaction, RNA was
116

added to Luna Universal One-Step RT-qPCR master mix (New England Bio Labs) and two RT-qPCR
primers at a final concentration of 0.4 µM. The following amplification cycle was run on a
QuantStudio 3 real-time PCR machine (ThermoFisher Scientific): 55 °C for 10 min, 95 °C for 1
min, followed by 95 °C for 10 sec and 60 °C for 1 min for 40 cycles. All genes were normalized to
beta Actin (ACTB) and expression was determined via relative quantification to lipofectamine
only carrier control. Gene specific primers for each gene of interest were ordered from
Integrated DNA Technologies and are as follows: ACTB: 5’-CACCATTGGCAATGAGCGGTTC-3’ and
5’-AGGTCTTTGCGGATGTCCACGT-3’, TBK1: 5’-GGATCACTGCCATTTAGACCC-3’ and 5’CAGGCATGTCTCCACTCCAG-3’ (PrimerBank 309747068c3), KRT14: 5’TGAGCCGCATTCTGAACGAG-3’ and 5’-GATGACTGCGATCCAGAGGA-3’ (PrimerBank 83641893c1),
HNRNPA1: 5’-TCAGAGTCTCCTAAAGAGCCC-3’ and 5-ACCTTGTGTGGCCTTGCAT-3’ (PrimerBank
83641893c1).

3.5.6 Plasmids and cloning
A sequence containing two BSMBI restriction sites flanked by hnRNPA1 recruiting loops (ARLs)
was cloned into PCDNA 3.1+ (Invitrogen) behind the CMV promotor between NheI and XbaI
restriction sites, upstream of the polyadenylation sequence to create a Golden Gate vector for
ARO constructs. This vector was then used to clone all additional ARO constructs except for
scrOligo-ARL, Oligo, ARL-Oligo, and Oligo-ARL (Figure 3.2A) which were cloned into the same
locus via Gibson assembly. All Golden Gate cloned constructs were ordered as two single-strand
DNA oligos (Integrated DNA Technologies) and annealed such that overhangs were compatible
with the Golden Gate ARO vector. Once cloned, these annealed oligos served as the targeting
oligos for the AROs. Single-strand RNA ARO oligos were ordered directly from IDT (Integrated
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DNA Technologies) and contained two phosphorothioate bonds at each end to protect the RNA
from degradation by exonucleases. The sequence used for the ARL was as follows: 5’GGATCCATTCGTAGGAGGAACGGATCC-3’. Sequences for targeting oligos in AROs used in
experiments are as follows. ARL-Oligo-KRT14 -ARL: 5’CCAGAGGAGAACTGGGAGGAGG-3’,
scrambledARL-Oligo: 5’-TGTGGCGAGTAGACTCGAAG-3’, ARL-TBK1-O1-ARL: 5’GTTCCCTGAGAACTGGAAAG-3’, ARL-TBK1-O2-ARL: 5’-CCTGAAGACTGGTTTCTATT-3’, ARL-TBK1O3-ARL: 5’- TCTGCCAGTGATCCACCTGG-3’, ARL-TBK1-O4-ARL: 5’- CTTCTTGATGTGCCCATGCG-3’,
ARL-TBK1-O6-ARL: 5’- TCTGTCTTTCGGATGAGTGC-3’.
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Figure 3.1

Figure 3.1: Overview of hnRNPA1 recruiting molecules (AROs). (A) Each ARO consists of two
parts, a 20 bp hnRNPA1 recruiting loop derived from HIV exon splicing silencer 3, which recruits
hnRNPA1 by binding to RNA binding domain RRM1, and an antisense targeting domain consisting
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of 20-25 base pairs of RNA complementary to a sequence on a target pre-mRNA. (B) The
hypothesized mechanism of AROs. 1. In the absence of AROs splicing occurs normally. 2. The
binding of an ARO to its pre-mRNA target recruits hnRNPA1 and displaces SR proteins and
spliceosome machinery (U2, U2AF65/35, and U1). 3. We hypothesize this causes repression of
splicing resulting in exon skipping or intron inclusion. This would cause frameshifts in the mRNA
leading to the presence of premature termination codons (PTCs) in the reading frame upstream
of exonic junction complexes (EJCs). UPF1 would then recognize these sites as mis-spliced mRNA
and degrade the RNA by non-sense mediated decay.
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Figure 3.2

Figure 3.2: Plasmid expressed AROs knock down KRT14 in human keratinocytes (HaCat cells). (A)
Visual representation of each ARO and controls. 1. scrOligo-ARL is a scrambled targeting oligo
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with an intact hnRNPA1 recruiting loop (ARL). 2. Oligo is a targeting oligo with homology to Exon
7 of KRT14. 3. ARL-Oligo is the targeting oligo with an ARL on the 5’ end of the construct relative
to the targeting domain. 4. Oligo-ARL is the targeting oligo with an ARL on the 3’ end of the
construct relative to the targeting domain. 5. ARL-Oligo-ARL is a construct with ARLs attached to
both the 5’ and 3’ ends of the targeting domain. (B) Fold change of KRT14 transcript expression
relative to a carrier only lipofectamine control RT-qPCR. Cells were lipofected with plasmid for 48
hours and then harvested for RNA extraction. Green bars indicate plasmid experiments while
blue bars indicate experiments with siRNA designed to knock down hnRNPA1. Three replicates
were performed. Error bars show standard deviation between replicates. A Student’s t test was
used to determine significance.
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Figure 3.3

Figure 3.3: Plasmid expressed AROs targeting exon 14 knock down TBK1 RNA expression in
human keratinocytes (HaCat cells). All AROs were expressed with ARLs attached to the 3’ and 5’
ends of the targeting oligo. (A) Location of targeting oligo homology to exon 14 of TBK1. (B) Fold
change of TBK1 transcript expression relative to a carrier only lipofectamine control RT-qPCR.
Cells were lipofected with plasmid for 48 hours and then harvested for RNA extraction. Three
replicates were performed. Error bars show standard deviation between replicates. A Student’s
t-test was used to determine significance.
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Figure 3.4

Figure 3.4: Synthesized single-strand RNA oligonucleotides knock down KRT14 expression across
two cell types. (A) Synthesized ssRNAs with phosphorothioate bonds on the first two and last
two bases administered via lipofection to HaCat cells at varying concentrations. ARL-Oligo-ARL
refers to a ssRNA with two hnRNPA1 recruiting loops on either side of the targeting domain. ARL127

Oligo is composed of a single hnRNPA1 recruiting loop fused to the 5’ end of an RNA targeting
sequence. A previously validated siRNA against KRT14 was used as a positive control at each
concentration. Cells were harvested 48 hours post lipofection and fold change was determined
relative to a lipofectamine carrier only control. (B) The single ARL-Oligo ssRNA and siRNA
targeting KRT14 were lipofected into SCC9 cells. As previously, cells were harvested 48 hours
post lipofection and fold change was determined relative to a lipofectamine carrier only control.
Three replicates were performed in each experiment. Error bars show standard deviation
between replicates. A Student’s t-test was used to determine significance.
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Figure 3.5

Figure 3.5: AROs show a functional phenotype in a cancer invasion model. (A) As previously,
siRNA targeting KRT14 and an ssRNA ARO with a single hnRNPA1 recruiting loop fused to the 5’
end of a KRT14 targeting oligo were administered at 100 nM via lipofection in SCC9 cells and
grown for 48 hours. 20,000 cells were seeded inside a matrigel-coated transwell for a Boyden
chamber invasion assay and allowed to migrate through the pores to the other side of the
membrane for 24 hours. Cells were then stained with crystal violet and invading cells were
imaged and counted. Two replicates were preformed of this experiment. Error bars show
standard deviation between replicates. A Student’s t test was used to determine significance. (B)
Representative images of crystal violet stained invading cells in each condition. (C) Protein
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abundance of KRT14 in cells lipofected with either ARO (ssRNA ARL-Oligo) or anti-KRT14 siRNA at
a final concentration of 100 nM. Each condition was performed in triplicate and total protein was
harvested 48 hours after lipofection. Western blots were preformed using KRT14 mouse primary
antibody and an anti-mouse HRP conjugated secondary antibody, and total protein load using a
stain free gel was used as a loading control for normalization.
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Chapter 4:
Conclusions and future directions
Throughout my graduate education I have had the privilege of working on several projects that
have allowed me to contribute to emerging biotechnologies. The conception of an idea is only
the beginning. It takes hard work, objectivity, and most of all adaptability to bring such concepts
to fruition. Biology is complex and often surprising. When one sets out to develop new
technology in biology, you are often left surprised by how all the pieces we thought we
understood come together in unexpected ways. Sometimes what you create only gets you part
of the way towards an ambitious goal. Other times, you create something entirely novel, but find
that the tool you have created works best outside the scope of your original vision. Finally, there
are those times when all the pieces behave as expected and the work goes according to plan.
Regardless of the outcome, it is important to keep an open mind to all the ways the technology
you develop can be used.

4.1 Digital analysis of proteins by end sequencing
In my first project, digital analysis of proteins by end sequencing (DAPES), we set out to develop
a highly parallel, wide dynamic range, protein sequencing platform. While many mature
technologies exist to sequence RNA and DNA, few similar options are available for the proteome.
While RNA works as a proxy for protein expression, it is not always a reliable indicator of protein
expression. Some RNAs may be expressed at high transcript levels, but their proteins may be
degraded quickly. Other proteins may be extremely stable and accumulate at higher levels than
what one would expect by only looking at RNA. Having a technology for proteins that paralleled
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next generation sequencing of nucleotides would greatly help us understand the interplay
between RNA transcript and protein expression.

While the technology has yet to be fully realized, my work on the project allowed me to develop
novel and useful biochemistry techniques that allowed for the attachment of peptides and
proteins to low background surfaces for nanofluidic and TIRF microscopy. Through my
experiments with PEG-maleimide, I developed a way to selectively attach peptides to a nanogel
and then deactivate the nanogel through pH hydrolysis, converting it into a low background
surface. This technology has numerous applications in the field of microfluidics, such as in viral
testing kits, where proteins such as antigens need to be attached to low background surfaces for
molecular probing and assays. In addition to my work on this nanogel surface, I created a system
to selectively link a biotin acceptor peptide to a peptide or protein of interest through a cystine
thiol maleimide bond. I then demonstrated that a second protein fused with BirA could be used
to tag the linked protein with biotin and that this tag could be observed at single molecule levels
through TIRF microscopy. In its current state, this technology could be used to amplify the signal
of transient protein-protein interactions on a chip or find use in biomarker devices. Peptides
from a serum sample could be attached to a microfluidic device and series of BirA fused proteins
could be passed through the device to create a profile of interactions. The number of proteins in
the sample tagged by the BirA probes could then be visualized via TIRF microscopy and
quantified on a single molecule level. This could allow for the detection of molecules at
extremely low concentrations or for the quantification of protein-protein interactions with high
dissociation constants (Kd) that can be otherwise difficult to visualize.
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The next steps for this project would be to develop and characterize more tRNA synthetase BirA
probes and to experiment with ways to recycle biotin acceptor peptides on peptide linker
molecules. To this end 2,3-dibromomaleimide seems promising as a repeatable and recyclable
attachment schema for peptide-peptide bonds, however, much work will need to be done to
understand the optimal conditions for this chemistry within the flow cell. While these two
milestones still need to be overcome, I believe DAPES has the potential to have a major impact
on the world of proteomics and overcome many of the limitations of current technologies.

4.2 Internal RNA identifier sequencing
In my second project, internal RNA identifier sequencing, I developed a way to use trans-splicing
to barcode endogenous RNA without the need for cell separation or tissue dissociation. I also
developed a computational pipeline that allows these transcripts to be sequenced in bulk via
next generation sequencing and sorted via barcodes. While the original goal of this project was
to use IRIS to barcode transcripts for single cell RNA sequencing experiments, an unexpected use
of this technology came from the realization that it could also be used as a screen for exonic
splice regulatory motifs, and RNA trans-splicing molecules, used as transient RNA therapeutics.
While further improvements in trans-splicing efficiency could be explored to make IRIS a better
technology for single cell RNA sequencing experiments, IRIS and the associated computational
pipeline have already been developed to the point where they can be used for screening
purposes. Using data generated from a barcoded IRIS experiment, I was able to demonstrate
significant enrichment in known exonic splice silencers (ESSs) within the unspliced barcodes of
IRIS. Future work should be done on this data set to explore new motifs enriched for in these
barcodes and follow them up computationally and experimentally. On the RTM front, I have
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developed an adapted IRIS protocol that successfully enriches for a gene specific trans-splicing
event, and shown that we are able to barcode and sequence this trans-splicing. The next step in
this direction would be to clone an IRIS library of barcoded RTM binding domains targeting a
specific splice junction and demonstrate that IRIS can be used to screen for the best locations to
target RTMs. I believe IRIS could have a significant impact in both ESR research and RTM
screening and am excited by the possibilities in both areas.

4.3 hnRNPA1 recruiting oligonucleotides
My final project was the development of hnRNPA1 recruiting oligonucleotides (AROs), short RNA
sequences capable of knocking down target transcript by recruiting the RNA binding protein
hnRNPA1. Targeted gene knockdown has become one of the most powerful tools in molecular
biology and holds substantial promise in therapeutic applications. Through my work on this
project, I was able to show that RNA binding loops could be bound to targeting oligos and used
to direct RNA binding proteins. I was also able to show that these constructs work both when
expressed from plasmids and as synthesized RNAs that can be directly delivered to cells. This was
significant as there are few technologies available that can seamlessly transition between
construct-based screening and the synthesis of biologically functional molecules. Finally, I was
able to show that these synthesized oligonucleotides were able to knockdown KRT14 in a
squamous cell carcinoma line and had the expected phenotype of reducing invasive potential.

Moving forward with this project, I would like to see more work done on the mechanism of
AROs. While I was able to show that AROs are hnRNPA1 dependent, there are two ways
recruitment of this protein could result in transcript knockdown. First, it is possible that AROs are
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working as originally intended by interfering with splice site junctions, repressing splicing, and
leading to transcript degradation by nonsense-mediated decay. This is testable by knocking
down UPF1, a protein that is necessary for nonsense-mediated decay, using siRNAs. If AROs are
nonsense mediated decay dependent, they should no longer function to knockdown transcript in
the absence of UPF1. Another possibility is that hnRNPA1 is shorting the poly-A tail of the
transcript through alternative polyadenylation (APA). This could be assayed for in several ways.
One method would be to create cDNA from an ARO targeted transcript using oligo(dT) (as a first
strand synthesis primer) and look for differences in cDNA length on a gel in plus and minus ARO
conditions. Another way would be to sequence the 3’ ends of transcripts via either next
generation sequencing or TA cloning and sanger sequencing of clones. In addition, I would also
like to see AROs applied to additional transcripts across a variety of exon locations. It would be
interesting to see if AROs functioned equally well on exons at the beginning or ends of
transcripts. If AROs targeted towards the terminal exon or 3’ UTR of transcripts still functioned,
this would be a very interesting observation as the nonsense-mediated decay mechanism should
have no exon junction complexes bind to, to determine premature termination codons, and
should not be compatible with this result. Finally, I would like to see AROs incorporated into a
lentiviral library and used to screen for AROs that enrich a specific phenotype. Afterwards, the
top ARO hits would be synthesized as oligos to see if the same phenotype could be replicated via
direct delivery. This would be the proof-of-concept experiment necessary to fully demonstrate
the power of AROs to transition between screen and the development of biologically functional
molecules.
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4.4 Closing remarks
As stated in my preface, I believe that technological innovation opens new doors for biological
research. I hope that my contributions to the field will have a positive impact in biological
research, provide new ways to ask questions, and provide inspiration for future technologies. In
conclusion I have worked on several technology projects that have both added to our body of
knowledge and opened new ways for us to understand the world around us. I hope that you
have enjoyed reading this thesis and that you found interest and value in work described within.
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